

**This item is the archived peer-reviewed author-version of:**

Surgery versus conservative treatment for traumatic acute subdural haematoma : a prospective, multicentre, observational, comparative effectiveness study

**Reference:**

van Essen Thomas A., Lingsma Hester F., Pisica Dana, Singh Ranjit D., Volovici Victor, den Boogert Hugo F., Younsi Alexander, Peppel Lianne D., Heijnenbroek-Kal Majanka H., Ribbers Gerard M., ....- Surgery versus conservative treatment for traumatic acute subdural haematoma : a prospective, multicentre, observational, comparative effectiveness study

The lancet neurology - ISSN 1474-4465 - 21:7(2022), p. 620-631

Full text (Publisher's DOI): [https://doi.org/10.1016/S1474-4422\(22\)00166-1](https://doi.org/10.1016/S1474-4422(22)00166-1)

To cite this reference: <https://hdl.handle.net/10067/1897490151162165141>

1 **Surgery versus conservative treatment for traumatic acute subdural**  
2 **hematoma: a prospective, multicentre, comparative effectiveness study**

3

4 Thomas A. van Essen (corresponding author)<sup>1</sup>, MD MSc

5 Prof. Hester F. Lingsma<sup>2</sup>, PhD

6 Dana Pisciă<sup>2,3</sup>, MD

7 Ranjit D. Singh, MD<sup>1</sup>

8 Victor Volovici<sup>2,3</sup>, MD PhD

9 Hugo F. den Boogert<sup>4</sup>, MD

10 Alexander Younsi<sup>5</sup>, MD PhD

11 Lianne D. Peppel<sup>6</sup>, MSc

12 Majanka H. Heijenbrok-Kal<sup>6</sup>, PhD

13 Prof. Gerard M. Ribbers<sup>6</sup>, MD PhD

14 Robert Walchenbach<sup>1</sup>, MD

15 Prof. David K. Menon<sup>7</sup>, MD PhD

16 Prof. Peter Hutchinson<sup>8,9</sup>, MD PhD

17 Prof. Bart Depreitere<sup>10</sup>, MD PhD

18 Prof. Ewout W. Steyerberg<sup>2,11</sup>, PhD

19 Em. Prof. Andrew I. R. Maas<sup>12</sup>, MD PhD

20 Godard C.W. de Ruiten<sup>1</sup>, MD PhD

21 Prof. Wilco C. Peul<sup>1</sup>, MD PhD

22 and the CENTER-TBI Investigators and Participants‡

23

24 Affiliations:

25 <sup>1</sup> University Neurosurgical Centre Holland, LUMC, HMC & Haga, Leiden-The Hague, The Netherlands

26

27 <sup>2</sup> Centre for Medical Decision Sciences, Department of Public Health, Erasmus MC - University Medical Centre  
28 Rotterdam, Rotterdam, The Netherlands

29

30 <sup>3</sup> Department of Neurosurgery, Erasmus MC - University Medical Centre Rotterdam, Rotterdam, The  
31 Netherlands

32

33 <sup>4</sup> Department of Neurosurgery, Radboud University Medical Centre, Nijmegen, The Netherlands

34

35 <sup>5</sup> Department of Neurosurgery, University Hospital Heidelberg, University of Heidelberg, Heidelberg, Germany

36

37 <sup>6</sup> Rijndam Rehabilitation and Department of Rehabilitation Medicine, Erasmus MC - University Medical Centre  
38 Rotterdam, The Netherlands

39

40 <sup>7</sup> Division of Anaesthesia, University of Cambridge and Addenbrooke's Hospital, Cambridge, United Kingdom

41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77

<sup>8</sup> Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge and Addenbrooke's Hospital, Cambridge, United Kingdom

<sup>9</sup> NIHR Global Health Research Group on Neurotrauma, University of Cambridge, Cambridge, United Kingdom

<sup>10</sup> Department of Neurosurgery, University Hospital Leuven, Leuven, Belgium

<sup>11</sup> Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, The Netherlands

<sup>12</sup> Department of Neurosurgery, Antwerp University Hospital, Edegem, and University of Antwerp, Belgium

‡ The CENTER-TBI Investigators and Participants and their affiliations are listed in the Supplementary appendix .

Corresponding author: Thomas A. van Essen  
Address: University Neurosurgical Centre Holland, Leiden University Medical Centre, Haaglanden Medical Centre and Haga Teaching Hospital, Leiden and The Hague, Albinusdreef 2, 2333 ZA Leiden, The Netherlands  
Telephone: 003171 526 2109  
Fax: 003171 526 6987  
e-mail address: essen@lumc.nl

Wordcount: abstract 322, manuscript 3922

Number of tables: 2

Number of figures: 3

Number of panels: 1

Number of supplemental tables: 8

Number of supplemental figures: 6

78 **Summary**

79

80 **Background** Despite being well-established, acute surgery in traumatic acute subdural hematoma (ASDH) is  
81 based on low-grade evidence. We aimed to compare the effectiveness of a strategy preferring acute surgical  
82 evacuation with one preferring (initial) conservative treatment in ASDH.

83

84 **Methods** Using the observational, multicentre, European cohort CENTER-TBI, we conducted a prospective  
85 comparative effectiveness study among patients with ASDH, presenting within 24 hours after injury. In an  
86 instrumental variable analysis, we compared outcomes between centres according to treatment preference,  
87 measured by the case-mix adjusted proportion acute surgery per centre. The primary endpoint was functional  
88 outcome rated by the 6-months Glasgow Outcome Scale Extended, estimated with ordinal regression as a  
89 common odds ratio (OR), adjusted for prespecified confounders. Variation in centre preference was quantified  
90 with the median odds ratio (MOR).

91

92 **Findings** We included 1407 patients with ASDH from 65 centres. Acute surgical evacuation was performed in  
93 336 patients (24%), in 245 (73%) by craniotomy and in 91 (27%) by decompressive craniectomy. Delayed  
94 surgery after initial conservative treatment (n=982) occurred in 107 patients (11%). The proportion acute surgery  
95 ranged from 7 to 52% (IQR 13-35%) between centres with a twofold higher probability of receiving acute  
96 surgery for an identical patient in one versus another random centre (adjusted MOR for acute surgery 1.8 [ $p <$   
97 0.0001]). Centre preference for acute surgery over initial conservative treatment was not associated with better  
98 outcome (OR per 22% (IQR) more acute surgery in a centre 0.92 [95% CI 0.77-1.09]). This was consistent in  
99 the group of patients without unreactive pupils or a GCS of 15.

100

101 **Interpretation** Similar patients with ASDH, without an extremely poor or good prognosis at presentation, were  
102 treated differently due to varying treatment preferences. A treatment strategy preferring an aggressive approach  
103 of acute surgical evacuation over initial conservative treatment was not associated with better outcome.

104 Therefore, in a patient with an ASDH for whom a clinician sees no clear superiority in acute surgery vs.  
105 conservative strategy, initial conservative treatment may be considered.

106

107

108 **Funding** The *Hersenstichting Nederland* (the Dutch Brain Foundation), the European Commission seventh  
109 Framework Program, the Hannelore Kohl Stiftung (Germany), OneMind (USA), Integra LifeSciences  
110 Corporation (USA), and NeuroTrauma Sciences (USA).  
111

## 112 **Introduction**

113 Acute subdural hematoma (ASDH) is the most prevalent focal lesion in traumatic brain injury (TBI) and is  
114 associated with high mortality and long-term neurocognitive morbidity.<sup>1</sup> One of the cornerstones of treatment is  
115 immediate neurosurgical management: acute hematoma evacuation or initial conservative treatment with  
116 potential delayed surgery.<sup>2,3</sup>

117 In patients with rapid neurological deterioration due to a large ASDH the decision to operate in the acute phase  
118 is clear: without acute surgery a high intracranial pressure (ICP) will persist and the patient will die. In most  
119 cases however, the benefit of acute surgery is less clear and patients may - at least initially - be safely managed  
120 conservatively. It requires balancing surgery with potential complications against initial conservative treatment  
121 with a risk of early death and disability due to irreversible deterioration.

122 Current Brain Trauma Foundation (BTF) guidelines advise acute surgery for ASDHs thicker than 10 mm or with  
123 midline shift greater than 5 mm, irrespective of clinical condition or patient characteristics,<sup>4</sup> but the strength of  
124 underpinning evidence is low, with only non-comparative studies in small, selected populations.<sup>5-9</sup> In the  
125 emergency setting, without high-level evidence, neurosurgeons are left with intuition and experience, formed by  
126 regional training and centre treatment culture, to guide their decision.

127 Consequently, the threshold for ASDH surgical evacuation varies substantially between centres.<sup>10,11,12</sup> Strong  
128 treatment preferences deeply rooted in centres seem to underlie this practice variation and reflect a lack of  
129 equipoise, a necessary premise for a randomised controlled trial (RCT).

130 Practice variation, however, provides opportunities to study the effectiveness of interventions in clinical reality  
131 by relating treatment variation to outcome.<sup>13</sup> Within the large observational cohort study 'Collaborative  
132 European NeuroTrauma Effectiveness Research in TBI' (CENTER-TBI), designed as comparative effectiveness  
133 study, preferred local treatment strategies were accepted and exploited to estimate their effectiveness in real-life  
134 practice.<sup>14</sup> Our aim was to compare the effectiveness of a strategy of acute surgical evacuation with one  
135 preferring initial conservative treatment in patients with ASDH.

136 **Methods**

137 This report follows the Strengthening the Reporting of Observational Studies in Epidemiology-statement with  
138 instrumental variable (IV) recommendations.<sup>15,16</sup> The research question, design, outcomes, analysis, subgroups  
139 and sample size calculations were defined before patient enrolment and have been published.<sup>14</sup> CENTER-TBI is  
140 registered with ClinicalTrials.gov, number NCT02210221, and the Resource Identification Portal (RRID:  
141 SCR\_015582). This study corresponds to Stage A in the IDEAL Framework.<sup>17</sup>

142 **Study population**

143 Patients with TBI, presenting within 24 hours after trauma, with a brain CT and without pre-existing severe  
144 neurological disorders were included in CENTER-TBI, from 2014 through 2017, in centres across Europe and  
145 Israel.<sup>18,19</sup> For this study, we selected patients with ASDH regardless of size and presumed necessity for surgical  
146 treatment. We excluded brain dead patients and those considered by the treating physician to be not salvageable  
147 due to injury deemed unsurvivable, in whom active treatment was not indicated. Due to the design of comparing  
148 treatment preferences, the study population inherently reflects the “real-life” clinical dilemma who to surgically  
149 treat acutely (appendix p 16). However, for interpretation purposes, we restricted the main analysis also to those  
150 “clinical equipoise” patients, being those without an extreme prognosis on either side of the spectrum.  
151 Specifically, patients with one or two unreactive pupils (poor prognosis) and patients with a GCS 15 (relatively  
152 good prognosis) were excluded for this main analysis.

153 CENTER-TBI was conducted in accordance to Good Clinical Practice (CPMP/ICH/135/95). Informed consent  
154 by patients or legal representatives was obtained according to local legislations.

155 **Centre characteristics and data management**

156 Centre characteristics were collected in prior performed surveys.<sup>12,20</sup> Questions included the centre’s policy  
157 towards the threshold for acute surgery, which was used in sensitivity analyses (appendix pp 13-14). Other  
158 treatment decisions, such as prehospital care, possibly related to the surgical threshold can impact the internal  
159 validity of our study. We have therefore performed extensive cluster analysis, of which part is separately  
160 published.<sup>21</sup> The main conclusion was that treatment preferences within a centres are unrelated.

161 Data were collected by trained personnel using web-based case report forms (QuesGen Systems Incorporated,  
162 Burlingame, CA, USA), coded with the Common Data Elements scheme.<sup>22</sup> Complete CENTER-TBI  
163 methodology was published separately.<sup>23</sup>

164 **Interventions**

165 Acute surgery was defined as surgery directly after the first CT-scan, conservative treatment was defined as best  
166 medical management (after the first scan) with potential delayed surgery. Neurosurgeons were asked at each CT  
167 if and why surgery was indicated, checked by actual operating room transferal and by surgery codes/description.  
168 Surgical treatment was at the discretion of the treating neurosurgeon and consisted of ASDH evacuation by  
169 craniotomy or by additionally performing a (primary) decompressive craniectomy (DC), defined as craniotomy  
170 without bone flap replacement to allow for current or near-future brain swelling. If deemed necessary, surgery of  
171 concomitant skull or brain lesions was performed simultaneously. The initial conservative approach was defined  
172 as best medical management after the first scan, with clinical monitoring on the ward, medium-care- or  
173 (neurocritical) intensive care unit (ICU) and included possible ICP monitoring and delayed surgical evacuation).

#### 174 **Outcomes**

175 The primary outcome was the Glasgow Outcome Scale Extended (GOSE), an 8-point scale ranging from 1  
176 (death) to 8 (upper good recovery), at 6 months.<sup>24</sup> The use of the GOSE as a core global outcome measure is  
177 recommended by the interagency TBI Outcomes Workgroup and the International Mission for Prognosis and  
178 Analysis of Clinical Trials in TBI group (IMPACT Common Data Elements). Secondary outcomes included in-  
179 hospital mortality, progression on CT/MRI, hospital length of stay (days), discharge destination, and 6-months  
180 quality of life assessed with the brain injury-specific Quality of Life after Brain Injury Questionnaire (Qolibri).<sup>25</sup>  
181 Outcome assessments were standardized and administered by interview or postal questionnaire.<sup>18</sup>

#### 182 **Statistical analysis**

183 Baseline characteristics are presented using descriptive statistics and compared between treatment groups with  
184 standardized mean differences. Practice variation was described as the proportion (%), interquartile range [IQR])  
185 of patients undergoing acute surgery per centre. To quantify and compare the between-centre differences in acute  
186 surgery, we calculated the median odds ratio (MOR). The MOR quantifies treatment variation between centres  
187 that is not attributable to chance and not explained by other (case-mix) factors.

188 The outcomes were analysed with respect to centre treatment strategy (and not actual treatment) in instrumental  
189 variable (IV) analyses.<sup>26-28</sup> Specifically, this was a comparison of centres with different preferences for acute  
190 surgical evacuation, quantified by the case-mix adjusted probability of performing acute surgery (as opposed to  
191 initial conservative treatment) as observed per centre. To minimize the influence of chance, only centres with at  
192 least 15 patients were included. We presented baseline characteristics and the CRASH-CT-score, a validated  
193 baseline prognostic model,<sup>29</sup> across quartiles of the instrumental variable, i.e. the case-mix adjusted probability  
194 of performing acute surgery. The first category contains centres least likely to perform acute surgery, fourth



195 quartile contains centres most likely to perform acute surgery. The IV analysis is based on preference for acute  
196 surgery rates as a continuous variable, the quartiles are presented to provide insight in the comparability of  
197 patient populations across the instrument, which allows the reader to evaluate how comparable the patient  
198 characteristics are (IV assumption: the instrument is independent of confounders).<sup>16,30</sup>

199 The primary effect estimate was the adjusted common OR for a shift in the direction of a better outcome on the  
200 GOSE (proportional odds). This ratio was estimated with random-effects ordinal regression with the instrument  
201 (adjusted probability of performing acute surgery) as a continuous treatment variable. Random-effect accounts  
202 for other between-centre differences than the factors included in the model. Confounding was further addressed  
203 by adjusting for the predefined variables age, GCS, pupil reactivity, ASDH size and midline shift.<sup>14</sup> The  
204 common OR is presented as a comparison between the first and the fourth quartile (IQR) of the instrument (the  
205 adjusted probabilities for undergoing acute surgery) and can be interpreted as the odds for a more favourable  
206 outcome when comparing centres favouring a strategy of acute surgery to those favouring initial conservative  
207 treatment.

208 The main analysis was post-hoc repeated on those patients for whom clinical equipoise exists, as would have  
209 been done for a RCT. In this post-hoc analysis, we excluded patients without an extremely good (i.e. GCS 15) or  
210 an extremely poor (one or two unreactive pupils) prognosis. While most clinicians would agree that there is more  
211 equipoise in these patients, and thus intuitively feel that the results might be applicable to them, we did not  
212 define this analysis in the protocol and thus label it post-hoc.

213 To assess the consistency of the (ordinal) estimate and the plausibility of proportionality of the OR, we present  
214 ORs for multiple cut-offs on the GOSE.

215 The association of surgical preferences with outcome was also estimated by linear regression with the fixed  
216 effect centre coefficients as independent variable and the (continuous) mean GOSE per centre as dependent  
217 variable. These results are graphically represented in scatter plots.

218 Secondary outcomes were analysed with random-effects logistic and linear regression.

219 The primary, centre-level, analysis, was supplemented with several sensitivity analyses including predefined  
220 subgroup analyses. Specifically, one of the sensitivity analyses was an instrumental variable analysis using the  
221 surveyed centre's preference for the use of surgery, as captured through the prior performed provider profiling,  
222 as the instrumental variable. Additionally, we performed sensitivity and subgroup analyses on patient-level, with  
223 multivariable regression and propensity score matching. A consistency in estimates with the employed methods  
224 would strengthen our findings.<sup>31</sup> All sensitivity analyses were performed for the primary outcome.

225 The supplementary appendix provides additional methodological details for all analyses.

226 Power calculations showed that assuming inclusion of 1000 ASDH patients would provide 80% power to detect  
227 an OR of 0.6.<sup>14</sup>

228 Analyses were performed in R-software version 3.5.3 and RStudio version 1.1.463. Missing data were multiply  
229 imputed with the Multiple Imputation by Chained Equations (MICE) package (n=5), assuming to be missing at  
230 random.

231 Comparison of descriptive characteristics are presented with standardized mean differences (SMD) and p-values  
232 between compared groups. ORs and Beta's are presented with 95% confidence intervals (CIs) calculated by  
233 bootstrapping with 500 samples.

234 **Role of the funding sources**

235 The funding entities had no role in the design and conduct of the study; collection, management, analysis, and  
236 interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the  
237 manuscript for publication.

238

239 **Results**

240

241 **Patient characteristics**

242 Of 4559 patients with TBI, 1407 patients with ASDH were included. Acute surgery was performed in 336  
243 patients (25%), at a median of 3.8 (IQR 2.5 – 6.5) hours after injury (appendix pp 17-21). Eighty-nine cases had  
244 an extremely poor prognosis or were brain dead, resulting in 982 out of 1071 patients treated conservatively, of  
245 which 107 patients (11%) receiving delayed surgery (craniotomy or DC), at a median of 19.1 (IQR 8.1 – 84.6)  
246 hours after injury. Of the 336 patients acutely operated, 91 (27%) underwent a primary DC (Figure 1). Of the  
247 initial conservatively treated by medical management, 313 patients (32%) received ICP monitoring, 107 patients  
248 (11%) underwent delayed DC or craniotomy for an ASDH or ICH and 20 patients (2%) received a (delayed) burr  
249 hole drainage for a chronic subdural hematoma (appendix pp 18-22). After excluding patients from centres with  
250 fewer than 15 patients (n = 158), 1160 patients were included in the IV analysis, 292 patients with acute surgery  
251 and 868 with (initial) conservative treatment (Figure 1).

252 The acute surgery cohort had a lower GCS at presentation, larger ASDHs, and a greater proportion of  
253 accompanying large contusions compared to the conservative cohort (appendix pp 17-21). The main reason for  
254 acute surgery was ‘emergency’ (57%), while in mild/moderate TBI, ‘mass effect on CT’ was relatively more  
255 often the motivation for surgery compared to severe TBI (appendix pp 26-27). Ninety-two percent of patients  
256 with 1 nonreactive pupil and large hematoma received acute surgery.

257 The main reasons for not performing acute surgery were that the lesion was considered not to benefit from  
258 surgery (considered ‘no surgical lesion’) or had little mass effect. The main reasons for secondary surgery after  
259 initial conservative treatment were ‘(suspicion of) raised ICP’, ‘mass effect on CT’ and ‘clinical deterioration’  
260 (appendix pp 26-27). Ninety-three percent of patients with a GCS of 15 received conservative treatment  
261 (initially).

262 In 89 patients, neither treatment was performed because these patients were considered not salvageable due to  
263 injury deemed unsurvivable (appendix pp 26-27). These patients had severe clinical and radiological  
264 characteristics and an in-hospital mortality of 96% with a median time to death of 21 hours, preceded by a  
265 multidisciplinary treatment limiting decision in most patients (79%, appendix pp 22-25).

266

267 **Practice variation**

268 The proportion acute surgery ranged from 6.7 to 51.5% (IQR, 13.4-35.1%) between centres (appendix p 28).

269 Practice variation was low for patients with a GCS of 15, in whom initial conservative treatment varied between

270 91 and 100%, and for patients with one nonreactive pupil and a large hematoma of whom 100% received acute  
271 surgery in 13 out of 16 centres.

272 The MOR for acute surgery was 1.8 ( $p < 0.0001$ ), reflecting a nearly twofold higher probability of receiving  
273 acute surgery for an identical patient in one versus another random centre (Figure 2). This remained consistent  
274 when restricting to patients with both reactive pupils and a GCS  $< 15$ : proportion acute surgery ranging from 3.1  
275 to 47.6% (IQR, 14.3-36.2%) between centres with a MOR of 1.7 ( $p = 0.0244$ ). Furthermore, the a-priori  
276 reported thresholds for acute surgery, i.e. the centre treatment policies, were associated with the casemix-  
277 adjusted (observed) acute surgery rates, confirming that surgery rates reflect centre treatment preferences (Table  
278 1 and appendix p 15).

279 Despite differences in baseline characteristics, the predicted 6-month functional outcome of the CRASH-CT  
280 score was similar across centres (Table 1), reflecting a balance in patient populations between centres with  
281 varying surgical preferences. Findings were consistent when analyses were restricted to patients with both  
282 reactive pupils and a GCS  $< 15$  (appendix pp 29-32).

283 Formally, the testable assumptions for IV analyses were met (appendix p 33).

284 Thus, the widely differing surgical practices arise from centres that on average treat similar patients.

285

## 286 **Association with outcome**

287 Centre preference for acute surgery over initial conservative treatment was not associated with better outcome  
288 (adjusted common OR per 22% (IQR) more acute surgery in a centre 0.92 [95% CI 0.77-1.09], Table 2;  
289 appendix p 34). The ORs were consistent across multiple GOSE dichotomizations (Table 2). In the post-hoc  
290 analysis, excluding patients with one or two unreactive pupils and patients with GCS 15, the OR remained  
291 consistent (adjusted common OR per 22% (IQR) more acute surgery in a centre 0.91 [95% CI 0.72-1.18],  
292 appendix p 35). Subgroup analyses showed considerable practice variation and consistent ORs (appendix p 36).  
293 Centre preference for acute surgery was strongly, but non-significantly, associated with better outcomes in large  
294 hematomas (OR 2.7 [95% CI 0.86-8.32]).

295 In sensitivity analyses, the association remained consistent when using the predefined instrumental variable  
296 (high vs low threshold surgical centres OR 1.05 [95% CI 0.85 – 1.32]), including centres with more than 10  
297 patients instead of 15 ( $n = 1227$ , OR 0.87 [95% CI 0.66 – 1.0]), including the non-salvageable patients (with a  
298 poor prognosis deemed unsurvivable) (OR 1.01 [95% CI 0.87 – 1.27]) or excluding patients with unreactive  
299 pupils or GCS 15 ( $n = 730$ , OR 0.94 [95% CI 0.85 – 1.12] , appendix p 37).

300

301 Adjustment in multivariable regression and propensity score matching gave comparable estimates to the primary  
302 analysis (appendix pp 37-40). Specifically excluding patients with one or two unreactive pupils and patients with  
303 GCS 15, the ORs from the multivariable regression and the propensity score matching remained consistent  
304 (appendix 37). In patient-level subgroup analyses, surgery was associated with worse outcome for age under 65.  
305 Acute surgery in the elderly and in patient with moderate TBI was non-significantly associated with better  
306 outcome (Figure 3).

307

308 None of the secondary outcomes were different between groups (Table 2, appendix p 41).

309

310 **Discussion**

311 In this comparative effectiveness study, similar patients with ASDH were treated differently due to varying  
312 surgical treatment preferences, and therefore, clinical equipoise can be inferred. A treatment strategy preferring  
313 an aggressive approach of acute surgical evacuation over initial conservative treatment was not associated with a  
314 better outcome. Results were consistent when targeting patients in whom equipoise likely existed for surgical vs.  
315 conservative treatment.

316

317 In settings where RCTs are difficult to conduct and strong confounding by indication exists, observational  
318 studies using robust quasi-experimental approaches are a promising alternative.<sup>26,27</sup> The validity of our  
319 conclusions relies on whether the centre treatment rate is an appropriate instrumental variable. Our instrument  
320 was strongly associated with acute surgery and not associated with baseline prediction of outcome. The balanced  
321 confounding between centres allows to reliably infer a reasonable balance in the distribution of unmeasured  
322 confounding.<sup>27</sup> Yet, the observed practice variation might still partly result from residual prognostic differences.  
323 Therefore, we compared observed rates of surgery to centre policies captured during provider profiling and  
324 confirmed that the between-centre variation actually arises from provider preferences.<sup>12</sup> An a-priori reported low  
325 threshold for acute surgery was strongly associated with centres actually performing acute surgery more  
326 frequently for similar patients. Moreover, we showed that the organization of TBI care (in the same centres of  
327 the current study) was homogeneous, making residual confounding due to other local practice variations  
328 unlikely. To further disentangle the effect of the ASDH treatment strategy in a centre from other between-centre  
329 variations in care associated with outcome, the effect of the current treatment strategy on outcome was modelled  
330 with adjustment for other between-centre differences using a random-effect for centre.<sup>27</sup>

331 The findings were robust in predefined sensitivity analyses and subgroups. By excluding patients who, in the  
332 acute phase, did not receive active treatment due to poor prognosis, the results could have suffered from  
333 selection bias. Similar to cross-over in as-treated analysis in a RCT, the inclusion of this cohort for the  
334 effectiveness analyses may not have been independent from confounding.<sup>32</sup> However, we performed a sensitivity  
335 analysis on the entire cohort - thereby not selecting on treatment – and found a similar OR. Finally, immortal  
336 time bias has been addressed through the design in which we defined the treatment groups after the first CT  
337 (showing the ASDH), thereby aligning the start of the follow-up with treatment assignment.

338

339 In terms of clinical implication, the results should be interpreted more carefully than concluding no effect of  
340 surgery. First, estimating an overall effect of any (surgical) intervention in TBI is amenable to a neutral result  
341 due to averaging heterogeneous effects.<sup>33</sup> In acute neurosurgery several RCTs and comparative observational  
342 studies have stumbled over such ‘negative’ findings.<sup>34-37</sup>

343 Second, the interpretation of IV effect estimates differs from that of conventional analyses. The instrument is the  
344 centre treatment rate as a proxy for the surgeon’s treatment preference. Because an identical patient may be  
345 operated in one centre but not in another, it naturally follows that there is more than one valid treatment option.  
346 The results apply to patients for whom the neurosurgeon may be in equipoise, judging that more than one valid  
347 treatment option exists (appendix p 17). As this equipoise differs per centre, we cannot readily identify the  
348 relative contribution of each subgroup.<sup>38</sup> Some authors suggest that IV analysis provides information on whether  
349 patients’ outcome will improve when centres change their policy with respect to a specific intervention, rather  
350 than estimating an effect in individual patients.<sup>39,40</sup> In this study some extrapolation to patient-level effects may  
351 be appropriate, because the multivariable regression and propensity score matching resulted in similar estimates  
352 to the IV approach and all methods were reliable and implemented correctly.<sup>31</sup> The results should be appreciated  
353 in light of the conceptual difference between the employed methods.

354 Thus, although the inherent heterogeneous treatment effects in TBI and the indefinable patient population in IV  
355 effect estimation preclude recognizing an average treatment effect, the results suggest, when in equipoise  
356 regarding the decision to evacuate or not, no difference in outcome due to a centre’s treatment strategy.

357

358 Surgical evacuation of ASDH remains the cornerstone of treatment in life-threatening neurological  
359 deterioration.<sup>2</sup> All patients with one nonreactive pupil and a large hematoma were surgically treated acutely in  
360 nearly all participating centres, which had also been confirmed in our treatment preference surveys.<sup>10,12</sup> The  
361 strong – albeit non-significant – IV effect of surgery in the predefined subgroup with large hematoma is  
362 consistent with clinical experience that most patients would probably die if not operated, an effect that cannot be  
363 deduced from a RCT due to obvious constraints.

364 The estimates in the predefined age subgroups were consistent in patient- and centre-level analyses. A  
365 suggestion of benefit in the elderly is consistent with other comparative studies, although pre-existent co-  
366 morbidities are major drivers of outcome in the elderly with TBI.<sup>41-43</sup> The negative effect of acute surgery in  
367 patients younger than 65 rather contrasts the consensus of benefit of acute surgery in young ASDH patients. In

368 general, acute surgery may not always be necessary and a substantial proportion of patients initially managed  
369 conservatively have satisfactory outcomes.<sup>5-7,9,44</sup>

370

371 This study's strengths are the comparative effectiveness design using a contemporary, large cohort, with  
372 prospective, standardized data collection and predefined provider profiling. A limitation already discussed is the  
373 difficulty in interpretation of IV analysis. A RCT would obviously be ideal but is not easily feasible and also has  
374 methodological challenges.<sup>33</sup> Another limitation remains the possible residual confounding due to other local  
375 practice variations associated with surgical threshold, despite statistical adjustment (i.e. random effects term),  
376 despite the study design construction (IV analysis with a-priori confirmed neurosurgeon's preferences), and  
377 despite robust association estimates. We previously performed, a separate cluster analysis, with a broader  
378 medical domain view than neurosurgical treatment alone, to explore if the assumption of the absence of  
379 correlation between treatment choices holds.<sup>21</sup> The main conclusion was that, although correlations between  
380 treatment policies within domains (intracranial pressure monitoring, coagulation and transfusion, neurosurgery,  
381 prophylactic antibiotics, and more general ICU treatment policies) were found, it was not possible to cluster  
382 hospitals. Thus, specific treatment choices within the cohort do not correlate with other treatment choices of  
383 another domain. Importantly, the absence of correlation between domains was most pronounced for surgical  
384 treatment.

385 Limitation of the CENTER-TBI cohort in general is the focus on patients presenting to regional neurotrauma  
386 centres, with exclusion of pre-hospital deaths and patients with milder injuries. Participating institutions were  
387 mainly referral centres for neurotrauma and results might not be generalizable to other hospital settings and to  
388 every patient with a traumatic ASDH. For example, CENTER-TBI mainly included white males, reflecting the  
389 predominant white population of Europe and the fact that males are predominant in TBI, and thus the results are  
390 mostly applicable to white males.

391

392 An important power consideration is whether there could have been a clinically relevant treatment effect that  
393 was not detected with the current sample size. For power calculations the treatment effect was based on an OR  
394 0.6, deduced from the available evidence, suggesting comparable effect sizes for surgical ASDH  
395 evacuation.<sup>4,41,45</sup> Nevertheless, this assumed treatment effect is substantial and also smaller effects might be  
396 clinically relevant. However, all analyses show robust odds ratios close to 1. The uncertainty in these estimates is  
397 reported through confidence intervals; not by claiming non-significance in the p-values. So, while larger sample



398 sizes are desirable to reduce statistical uncertainty, the current results are highly relevant for clinical practice and  
399 reflects “real life” care among patients with ASDH referred to a dedicated neurotrauma centre.

400

401 Subsequent studies of surgery in ASDH are advised to be pragmatic RCTs, specifically targeted at those  
402 subgroups of patients likely to benefit from acute surgery, as explored in our study, in combination with previous  
403 evidence.

404

405 In conclusion, similar patients with traumatic ASDH, without an extremely poor or good prognosis at  
406 presentation, were treated differently across different centres due to varying treatment preferences. A treatment  
407 strategy preferring an aggressive approach of acute surgical evacuation over initial conservative treatment was  
408 not associated with better outcome. Therefore, in a patient with an ASDH for whom a clinician sees no clear  
409 superiority in acute surgery vs. conservative strategy, initial conservative treatment may be considered.

410

411 **Contributors**

412 TvE conceptualised the study, curated the data, analysed the data and drafted the manuscript including all tables  
413 and figures. DP assisted in the data curation. GdR, HL, ES, AM and WP assisted in the interpretation of the data  
414 and helped drafting the manuscript. AM, RW, GdR, WP (the clinical supervisors) and HL, ES (the statistical  
415 supervisors) supervised the methodology of the study protocol and supervised the study. TvE, HL, RW, ES, AM,  
416 GdR, and WP reviewed the manuscript multiple times. TvE, HL, VV, HdB, DM, PH, BD, ES, AM, GdR and  
417 WP were involved in the design of CENTER-TBI. All authors reviewed and approved the final version of the  
418 manuscript. TvE, DP and HL accessed and verified the analyses. All authors guarantee that the manuscript is an  
419 honest, accurate, and transparent account of the study being reported and that no important aspects of the study  
420 have been omitted. All authors had full access to all the data in the study and all authors had final responsibility  
421 for the decision to submit for publication.

422

423 **Declaration of interests**

424 AM declares consulting fees from PresSura Neuro, Integra Life Sciences, and NeuroTrauma Sciences. DKM  
425 reports grants from the UK National Institute for Health Research, during the conduct of the study; grants,  
426 personal fees, and non-financial support from GlaxoSmithKline; and personal fees from Neurotrauma Sciences,  
427 Lantmaan AB, Pressura, and Pfizer, outside of the submitted work. EWS reports personal fees from Springer,  
428 during the conduct of the study. All other authors declare no competing interests.

429

430 **Data sharing**

431 The datasets, which include individual participant data and a data dictionary defining each field in the set used or  
432 analysed during the current study, will be available upon reasonable request to the management committee of the  
433 CENTER-TBI study. Requests for data should be submitted online at <https://www.center-tbi.eu/data> or via email  
434 to [center-tbi@uza.be](mailto:center-tbi@uza.be). The data that will be made available comprise de-identified participant data. The  
435 predefined study protocol is published.<sup>14</sup> The statistical analysis plan, R-syntax, and informed consent forms will  
436 be made available upon request. To access any other data from CENTER-TBI, a proposal should be submitted  
437 and approved by the management committees of the CENTER-TBI study. A data access agreement with the  
438 management team of CENTER-TBI should be signed before access to the data will be granted.

439

440 **Acknowledgements**

441 The authors' work on this study is funded by the *Hersenstichting Nederland* (the Dutch Brain Foundation, grant  
442 number ps2014.06) for the Dutch Neurotraumatology Quality Registry (Net-QuRe)<sup>19</sup> and the European Union  
443 seventh Framework Program (grant 602150) for CENTER-TBI. Additional support for CENTER-TBI was  
444 obtained from the Hannelore Kohl Stiftung (Germany), from OneMind (USA), from Integra LifeSciences  
445 Corporation (USA) and from NeuroTrauma Sciences (USA). We thank all patients for their participation in the  
446 CENTER-TBI study. We also thank all principal investigators and researchers for their collaboration and  
447 support.

448

449 **References**

- 450 1 Maas AIR, Menon DK, Adelson PD, *et al.* Traumatic brain injury: integrated approaches to  
451 improve prevention, clinical care, and research. *The Lancet Neurology* 2017; **16**: 987–1048.
- 452 2 Munro D. The diagnosis and treatment of subdural hematoma. *N Engl J Med* 1934; **210**: 1–16.
- 453 3 Servadei F, Compagnone C, Sahuquillo J. The role of surgery in traumatic brain injury. *Curr*  
454 *Opin Crit Care* 2007; **13**: 163–8.
- 455 4 Bullock MR, Chesnut R, Ghajar J, *et al.* Surgical management of acute subdural hematomas.  
456 *Neurosurgery* 2006; **58**: S16–24–discussionSi–iv.
- 457 5 Wong. Criteria for conservative treatment of supratentorial acute subdural haematomas. *Acta*  
458 *Neurochir Wien* 2005; : 38–43.
- 459 6 Mathew P, Oluoch-Olunya DL, Condon BR, Bullock R. Acute subdural haematoma in the  
460 conscious patient: outcome with initial non-operative management. *Acta Neurochir* 1993; **121**:  
461 100–8.
- 462 7 Servadei F, Nasi MT, Cremonini AM, Giuliani G, Cenni P, Nanni A. Importance of a reliable  
463 admission Glasgow Coma Scale score for determining the need for evacuation of posttraumatic  
464 subdural hematomas: a prospective study of 65 patients. *The Journal of Trauma: Injury, Infection,*  
465 *and Critical Care* 1998; **44**: 868–73.
- 466 8 Compagnone C, Murray GD, Teasdale GM, *et al.* The Management of Patients with Intradural  
467 Post-Traumatic Mass Lesions: A Multicenter Survey of Current Approaches to Surgical  
468 Management in 729 Patients Coordinated by the European Brain Injury Consortium.  
469 *Neurosurgery* 2005; : 1183–92.
- 470 9 Feliciano CE, De Jesus O. Conservative management outcomes of traumatic acute subdural  
471 hematomas. *P R Health Sci J* 2008; **27**: 220–3.
- 472 10 van Essen TA, de Ruiter GCW, Kho KH, Peul WC. Neurosurgical Treatment Variation of  
473 Traumatic Brain Injury: Evaluation of Acute Subdural Hematoma Management in Belgium and  
474 The Netherlands. *Journal of Neurotrauma* 2017; **34**: 881–9.
- 475 11 Truong EI, Stanley SP, DeMario BS, *et al.* Variation in neurosurgical intervention for severe  
476 traumatic brain injury: The challenge of measuring quality in trauma center verification. *J*  
477 *Trauma Acute Care Surg* 2021; **91**: 114–20.
- 478 12 Essen TA, Boogert HF, Cnossen MC, *et al.* Variation in neurosurgical management of traumatic  
479 brain injury: a survey in 68 centers participating in the CENTER-TBI study. 2018; : 1–15.
- 480 13 Lingsma HF, Roozenbeek B, Li B, *et al.* Large Between-Center Differences in Outcome After  
481 Moderate and Severe Traumatic Brain Injury in the International Mission on Prognosis and  
482 Clinical Trial Design in Traumatic Brain Injury (IMPACT) Study. *Neurosurgery* 2011; **68**: 601–  
483 8.
- 484 14 van Essen TA, Volovici V, Cnossen MC, *et al.* Comparative effectiveness of surgery in traumatic  
485 acute subdural and intracerebral haematoma: study protocol for a prospective observational study  
486 within CENTER-TBI and Net-QuRe. *BMJ Open* 2019; **9**: e033513–8.
- 487 15 Elm von E, Altman DG, Eggers M, Pocock SJ, Gotsche PC, Vandenbroucke JP. The  
488 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement:  
489 guidelines for reporting observational studies. *The Lancet* 2007; : 1453–7.
- 490 16 Davies NM, Smith GD, Windmeijer F, Martin RM. Issues in the reporting and conduct of  
491 instrumental variable studies: a systematic review. *Epidemiology* 2013; **24**: 363–9.

- 492 17 McCulloch P, Altman DG, Flum DR, *et al.* No surgical innovation without evaluation: the  
493 IDEAL recommendations. *Lancet* 2009; **374**: 1105–12.
- 494 18 Maas AIR, Menon DK, Steyerberg EW, *et al.* Collaborative European NeuroTrauma  
495 Effectiveness Research in Traumatic Brain Injury (CENTER-TBI): a prospective longitudinal  
496 observational study. *Neurosurgery* 2015; **76**: 67–80.
- 497 19 Nederlands Trial Register [Internet]. Amsterdam: Academic Medical Center (The Netherlands).  
498 2004 Oct 26. Identifier Trial NL5761; 2016 July 28. Available from:  
499 <https://www.trialregister.nl/trial/5761>.
- 500 20 Cnossen MC, Polinder S, Lingsma HF, *et al.* Variation in Structure and Process of Care in  
501 Traumatic Brain Injury: Provider Profiles of European Neurotrauma Centers Participating in the  
502 CENTER-TBI Study. *PLoS ONE* 2016; **11**: e0161367.
- 503 21 Ceyisakar IE, Huijben JA, Maas AIR, Lingsma HF, van Leeuwen N. Can We Cluster ICU  
504 Treatment Strategies for Traumatic Brain Injury by Hospital Treatment Preferences?  
505 *Neurocritical care* 2021; published online Dec. DOI:10.1007/s12028-021-01386-y.
- 506 22 Commondataelements.ninds.nih.gov. National Institute of Neurological Disorders and Stroke.
- 507 23 Steyerberg EW, MSc EW, Sewalt C, *et al.* Case-mix, care pathways, and outcomes in patients  
508 with traumatic brain injury in CENTER-TBI: a European prospective, multicentre, longitudinal,  
509 cohort study. *The Lancet Neurology* 2019; **18**: 923–34.
- 510 24 Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the Glasgow Outcome Scale  
511 and the extended Glasgow Outcome Scale: guidelines for their use. *Journal of Neurotrauma*  
512 1998; **15**: 573–85.
- 513 25 Steinbuechel von N, Petersen C, Bullinger M. Assessment of health-related quality of life in  
514 persons after traumatic brain injury--development of the Qolibri, a specific measure. *Acta*  
515 *Neurochir Suppl* 2005; **93**: 43–9.
- 516 26 Brookhart MA, Rassen JA, Schneeweiss S. Instrumental variable methods in comparative safety  
517 and effectiveness research. *Pharmacoepidem Drug Safe* 2010; **19**: 537–54.
- 518 27 Cnossen MC, van Essen TA, Ceyisakar IE, *et al.* Adjusting for confounding by indication in  
519 observational studies: a case study in traumatic brain injury. *Clinical Epidemiology* 2018; **10**:  
520 841–52.
- 521 28 van Essen TA, Menon DK, Lingsma HF. Unmeasured Confounding in Observational Studies of  
522 Management of Cerebellar Intracranial Hemorrhage. *JAMA* 2020; **323**: 665–6.
- 523 29 MRC CRASH Trial Collaborators. Predicting outcome after traumatic brain injury: practical  
524 prognostic models based on large cohort of international patients. *BMJ* 2008; **336**: 425–9.
- 525 30 Boef AGC, Dekkers OM, le Cessie S, Vandenbroucke JP. Reporting instrumental variable  
526 analyses. *Epidemiology* 2013; **24**: 937–8.
- 527 31 Laborde-Castérot H, Agrinier N, Thilly N. Performing both propensity score and instrumental  
528 variable analyses in observational studies often leads to discrepant results: a systematic review.  
529 *Journal of Clinical Epidemiology* 2015; **68**: 1232–40.
- 530 32 Swanson SA, Robins JM, Miller M, Hernán MA. Selecting on Treatment: A Pervasive Form of  
531 Bias in Instrumental Variable Analyses. *American Journal of Epidemiology* 2015; **181**: 191–7.
- 532 33 Maas AIR, Menon DK, Lingsma HF, Pineda JA, Sandel ME, Manley GT. Re-Orientation of  
533 Clinical Research in Traumatic Brain Injury: Report of an International Workshop on  
534 Comparative Effectiveness Research. *Journal of Neurotrauma* 2012; **29**: 32–46.

535 34 Hutchinson PJ, Koliás AG, Timofeev IS, *et al.* Trial of Decompressive Craniectomy for  
536 Traumatic Intracranial Hypertension. *N Engl J Med* 2016; **375**: 1119–30.

537 35 Kuramatsu JB, Biffi A, Gerner ST, *et al.* Association of Surgical Hematoma Evacuation vs  
538 Conservative Treatment With Functional Outcome in Patients With Cerebellar Intracerebral  
539 Hemorrhage. *JAMA* 2019; **322**: 1392–12.

540 36 Shibahashi K, Sugiyama K, Tomio J, Hoda H, Morita A. In-hospital mortality and length of  
541 hospital stay with craniotomy versus craniectomy for acute subdural hemorrhage: a multicenter,  
542 propensity score-matched analysis. *Journal of Neurosurgery* 2019; : 1–10.

543 37 Skolnick BE, Maas AI, Narayan RK, *et al.* A Clinical Trial of Progesterone for Severe Traumatic  
544 Brain Injury. *N Engl J Med* 2014; **371**: 2467–76.

545 38 Swanson SA, Hernán MA. The challenging interpretation of instrumental variable estimates  
546 under monotonicity. *International Journal of Epidemiology* 2017; **47**: 1289–97.

547 39 Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of  
548 observational studies in the presence of treatment selection bias: effects of invasive cardiac  
549 management on AMI survival using propensity score and instrumental variable methods. *JAMA*  
550 2007; **297**: 278–85.

551 40 Maciejewski ML, Brookhart MA. Using Instrumental Variables to Address Bias From  
552 Unobserved Confounders. *JAMA* 2019; **321**: 2124–2.

553 41 van Essen TA, Dijkman MD, Cnossen MC, *et al.* Comparative Effectiveness of Surgery for  
554 Traumatic Acute Subdural Hematoma in an Aging Population. *Journal of Neurotrauma* 2019; **36**:  
555 1184–91.

556 42 Shimoda K, Maeda T, Tado M, Yoshino A, Katayama Y, Bullock MR. Outcome and Surgical  
557 Management for Geriatric Traumatic Brain Injury: Analysis of 888 Cases Registered in the Japan  
558 Neurotrauma Data Bank. *World Neurosurg* 2014; **82**: 1300–6.

559 43 Younsi A, Fischer J, Habel C, *et al.* Mortality and functional outcome after surgical evacuation of  
560 traumatic acute subdural hematomas in octa- and nonagenarians. *European journal of trauma and*  
561 *emergency surgery : official publication of the European Trauma Society* 2020; published online  
562 June. DOI:10.1007/s00068-020-01419-9.

563 44 Gernsback JE, Kolcun JPG, Richardson AM, Jagid JR. Patientem Fortuna Adiuvat: The Delayed  
564 Treatment of Surgical Acute Subdural Hematomas-A Case Series. *World Neurosurg* 2018; **120**:  
565 e414–20.

566 45 Seelig JM, Becker DP, Miller JD, Greenberg RP, Ward JD, Choi SC. Traumatic acute subdural  
567 hematoma: major mortality reduction in comatose patients treated within four hours. *N Engl J*  
568 *Med* 1981; **304**: 1511–8.

569

570 **Table 1. Baseline characteristics and prognostic risk across centres with different preferences**  
571 **for immediate treatment of acute subdural hematoma**

572

	Treatment preference (observed acute surgery rates) <sup>a</sup>				p value	SMD
	1 (<13%)	2 (13 – 24%)	3 (24 – 35%)	4 (> 35%)		
n	229	348	291	292		
Age (median [IQR])	60 [43, 75]	52 [35, 66]	59 [36, 72]	59 [43, 71]	0.27	0.08
Sex					0.27	0.10
Female	77 (44)	97 (28)	117 (40)	84 (28)		
Male	152 (66)	251 (72)	174 (60)	208 (71)		
White European	195 (85)	292 (84)	248 (85)	244 (84)	0.51	0.28
Years of education (median [IQR])	12 [10, 15]	12 [9, 15]	12 [10, 15]	12 [10, 16]	0.36	0.09
College or university education	37 (16)	83 (24)	49 (17)	55 (19)	0.05	0.22
Married or living with partner	114 (50)	174 (50)	147 (51)	149 (51)	0.21	0.28
Working before injury (%)	97 (42)	138 (40)	116 (40)	125 (43)	0.25	0.27
ASAPS (%)					0.54	0.13
Healthy	106 (46)	164 (47)	157 (54)	135 (46)		
Mild systemic disease	90 (39)	129 (37)	85 (29)	111 (38)		
Severe systemic disease	27 (12)	46 (13)	42 (14)	32 (11)		
Threat to life	0 (0)	1 (0)	3 (1)	0 (0)		
Unknown	6 (3)	8 (2)	4 (1)	14 (5)		
History of cardiovascular disease	85 (37)	109 (31)	98 (34)	118 (40)	0.07	0.21
Alcohol consumption <sup>b</sup>	86 (38)	93 (27)	102 (35)	77 (26)	0.0150	0.19
Injury mechanism and cause					0.57	0.28
High velocity trauma	84 (37)	110 (32)	92 (32)	87 (30)		
Incidental ground level fall	104 (45)	193 (55)	151 (52)	143 (49)		
Highest trained bystander (%)					0.55	0.23
None	15 (7)	19 (5)	17 (6)	15 (5)		
Untrained person (bystander)	1 (0)	6 (2)	6 (2)	2 (1)		
Paramedic	57 (25)	100 (29)	56 (19)	64 (22)		
Nurse	43 (19)	43 (12)	63 (22)	46 (16)		
Physician	59 (26)	92 (26)	72 (25)	79 (27)		
Medical rescue team	53 (23)	87 (25)	73 (25)	83 (28)		
Secondary referral (%)	59 (26)	85 (24)	75 (26)	65 (22)	0.41	0.08
Arrival Method (%)					0.19	0.22
Ambulance	167 (73)	268 (77)	212 (73)	216 (74)		
Helicopter	36 (16)	36 (10)	34 (12)	35 (12)		
Medical mobile team	11 (5)	23 (7)	18 (6)	26 (9)		

CPR (%)	8 (3)	12 (3)	10 (3)	4 (1)	0.19	0.14
IV Fluids (%)	86 (38)	129 (37)	121 (42)	124 (42)	0.30	0.10
Intubation (%)	70 (31)	97 (28)	88 (30)	97 (33)	0.63	0.08
Supplemental oxygen (%)	111 (48)	170 (49)	138 (47)	144 (49)	0.0221	0.24
Ventilation (%)	69 (30)	87 (25)	76 (26)	88 (30)	0.31	0.13
Hypoxia (%) <sup>c</sup>					0.54	0.13
No	204 (89)	279 (80)	263 (90)	248 (85)		
Definite	9 (4)	20 (6)	19 (7)	17 (6)		
Suspect	7 (3)	9 (3)	2 (1)	10 (3)		
Hypotension (%) <sup>d</sup>					0.19	0.20
No	200 (87)	301 (86)	272 (93)	246 (84)		
Definite	18 (8)	12 (3)	6 (2)	18 (6)		
Suspect	2 (1)	4 (1)	7 (2)	7 (2)		
Any major extracranial injury (%) <sup>e</sup>	82 (36)	131 (38)	128 (44)	124 (42)	0.15	0.14
GCS baseline (median [IQR])	13 [4, 15]	12 [7, 15]	10 [6, 14]	11 [6, 14]	0.05	0.10
GCS motor baseline (median [IQR])	6 [1, 6]	6 [3, 6]	5 [1, 6]	5 [2, 6]	0.31	0.02
Pupils (%)					0.62	0.09
Both reacting	200 (87)	305 (88)	229 (79)	243 (83)		
One reacting	12 (5)	17 (5)	22 (7)	23 (8)		
Both unreacting	17 (7)	26 (7)	40 (14)	26 (9)		
Any focal neurological deficit (%)					0.29	0.14
No	149 (65)	233 (67)	190 (65)	208 (71)		
Yes	36 (16)	27 (8)	31 (11)	32 (11)		
Unknown	44 (19)	88 (25)	70 (24)	52 (18)		
Anti-coagulants or platelet aggregation inhibitors (%)					0.0128	0.31
No	162 (71)	271 (78)	216 (74)	205 (70)		
Anti-coagulants	31 (14)	20 (6)	29 (10)	18 (6)		
Platelet inhibitors	26 (11)	42 (12)	34 (12)	44 (15)		
Both	2 (1)	0 (0)	5 (2)	3 (1)		
Unknown	8 (3)	15 (4)	7 (2)	22 (8)		
Total volume of ASDH (cm <sup>3</sup> , median [IQR])	11 [3, 25]	14 [4, 31]	21 [6, 55]	17 [5, 53]	0.0001	0.39
CT ASDH = large (%) <sup>f</sup>	44 (19)	77 (22)	88 (30)	100 (34)	0.0002	0.34
CT midline shift (%) <sup>g</sup>	88 (38)	139 (40)	121 (42)	106 (36)	0.68	0.04
CT contusion (%)					0.59	0.12
No	95 (41)	122 (35)	128 (44)	104 (36)		
Small	105 (46)	187 (54)	126 (43)	148 (51)		
Large	28 (12)	38 (11)	30 (10)	39 (13)		
Unknown	1 (0)	1 (0)	7 (2)	1 (0)		
CT subarachnoid haemorrhage (%)					0.10	0.22



No	76 (33)	117 (34)	101 (35)	104 (36)		
Basal	13 (6)	31 (9)	23 (8)	26 (9)		
Cortical	115 (50)	158 (45)	132 (45)	118 (40)		
Basal and Cortical	25 (11)	42 (12)	35 (12)	44 (15)		
CT basal cisterns absent/compressed (%)	37 (16)	66 (19)	64 (22)	54 (18)	0.56	0.06
Mean predicted 6-month unfavourable outcome (GOS $\leq$ 3, %, median [IQR]) <sup>h</sup>	59 [31, 77]	48 [26, 65]	56 [31, 75]	56 [28, 73]	0.28	0.10
Centre characteristics						
Academic hospital (vs. non-academic)	229 (100)	348 (100)	210 (72)	292 (100)	NA	<0.0001
Number of beds (%)	925 [448, 1238]	841 [721, 1160]	953 [710, 1448]	898 [711, 1271]	0.59	0.43
Residency program neurosurgery	229 (100)	348 (100)	291 (100)	292 (100)	NA	<0.0001
Trauma centre designation					<0.01	0.58
- Level I	129 (70)	316 (95)	272 (100)	203 (100)		
- Level II	0 (0)	17 (5)	0 (0)	0 (0)		
- Level III	54 (30)	0 (0)	0 (0)	0 (0)		
Urban location (vs. suburban and rural location)	229 (100)	348 (100)	291 (100)	292 (100)	NA	<0.0001
Neurosurgeon staffing (FTE)	12 [10, 14]	12 [11, 12]	10 [8, 14]	7 [6, 11]	0.08	0.49
Number of surgeries for ASDH in 2013	62 [20, 99]	20 [14, 35]	24 [24, 25]	24 [8, 42]	0.16	0.60
Low threshold policy for acute surgery in ASDH <sup>i</sup>	46 (20)	66 (19)	170 (58)	179 (61)	<0.0001	0.92

573

574 Abbreviations: AIS, Abbreviated Injury Scale; ASAPS, American Society of Anesthesiologists  
575 classification system; ASDH, acute subdural hematoma; FTE, full time equivalent; GCS, Glasgow  
576 Coma Scale; GOS(E), Glasgow Outcome Scale Extended; IQR, interquartile range.

577

578 <sup>a</sup> Treatment preference as defined by the case-mix adjusted probability of undergoing acute surgery  
579 (as opposed to initial conservative treatment) based on the observed acute surgery rates per centre.  
580 The first category is less aggressive than the second and the second is less aggressive than the third  
581 and so forth. Importantly, the IV analysis used the acute surgery rates as continuous preference, the  
582 quartiles are presented for purposes of interpretability of baseline comparability.

583

584 <sup>b</sup> On presentation the behavioural history of the patient was recorded. This variable reflects the past  
585 three months consumption of alcoholic beverages (beer, wine, spirits) (>2/day).

586

587 <sup>c</sup> Second insult during the pre-hospital or ER phase, defined as PaO<sub>2</sub> < 8 kPa (60 mmHg)/SaO<sub>2</sub> <  
588 90%. "Suspected" was scored if the patient did not have documented hypoxia by PaO<sub>2</sub> or SaO<sub>2</sub>, but  
589 there was a clinical suspicion, as evidenced by for example cyanosis, apnoea or respiratory distress.

590

591 <sup>d</sup> Second insult during the pre-hospital or ER phase, defined as systolic BP < 90 mmHg. "Suspected"  
592 was scored if the patient did not have a documented blood pressure, but was reported to be in shock  
593 or have an absent brachial pulse (not related to injury of the extremity).

594

595 <sup>e</sup> AIS ≥ 3.

596

597 <sup>f</sup> Large is defined as larger than 25 cm<sup>3</sup>.

598

599 <sup>g</sup> Midline shift present is classified as being more than 5 mm.

600

601 <sup>h</sup> TBI severity as summarized in predicted unfavourable outcome, proportion with a Glasgow Outcome  
602 Scale ≤ 3, based on CRASH-CT variables.

603

604 <sup>i</sup> Before patient inclusion in CENTER-TBI, treatment policies per centre were captured by provider  
605 profile surveys, including the policy towards acute surgery. The resulting threshold for acute ASDH  
606 surgery is dichotomized based on this distinction: 'Low', low threshold for surgery; 'High', high  
607 threshold for surgery).

608

609 **Table 2. Primary and secondary outcomes and association with acute surgery**

610

	Treatment preference (observed acute surgery rates)				Effect variable	Adjusted value (95% CI) <sup>a</sup>
	1 (<13%)	2 (13 – 24%)	3 (24 – 35%)	4 (> 35%)		
Primary outcome: GOSE at 6 months (median [IQR])	5 [3 to 8)	6 [3 to 7]	5 [3 to 7]	5 [3 to 7)	Common odds ratio	0.92 (0.77 – 1.09)
Secondary outcomes						
In-hospital mortality	37 (16)	42 (12)	56 (19)	52 (18)	Odds ratio	1.04 (0.78 – 1.40)
GOSE of 7 or 8 (%)	92 (40)	128 (37)	88 (30)	96 (33)	Odds ratio	0.95 (0.76 – 1.12)
GOSE of 5-8 (%)	141 (57)	231 (66)	158 (54)	153 (53)	Odds ratio	0.88 (0.74 – 1.10)
GOSE of 4-8 (%)	163 (67)	249 (71)	183 (63)	165 (57)	Odds ratio	0.76 (0.61 – 0.99)
Qolibri (median [IQR]) at 6 months <sup>b</sup>	80 [64 to 92]	74 [62 to 83]	66 [51 to 86]	76 [64 to 85]	Beta	0.92 (-1.05 – 2.89)

611

612 Abbreviations: CI, confidence interval; GOSE, Glasgow Outcome Scale Extended; IQR, interquartile  
613 range; Qolibri, Quality of Life after Brain Injury Scale;

614

615 <sup>a</sup> Estimates from random-effects multivariable logistic regression with the instrument, adjusted  
616 probability of performing acute surgery as treatment variable. Confounding was furthermore  
617 addressed by adjusting for the a-priori defined variables age, GCS, pupil reactivity, hematoma size  
618 and midline shift. The (common) odds ratio are presented as comparisons between the first quartile  
619 and the fourth quartile (IQR) of the instrument (the adjusted probabilities for undergoing acute  
620 surgery).

621

622 <sup>b</sup> Qolibri is a standardized health specific quality of life measure specifically designed for and validated  
623 for outcome assessment in patients with brain injury. It is a numerical scale with scores ranging from 0  
624 to 100 with higher scores indicating a better quality of life. The score was available for 130 patients of  
625 the acute surgery group, 596 patients of the conservative management group.

626

627

628 **Figure 1: Flow diagram of study population and data analyses**

629

630 **Figure 2: Between-centre (A) and between-country (B) differences in acute surgery**

631 (A) The x-axis presents the log odds of the adjusted acute surgery rates per centre. A logistic random-effects model, adjusted for the predefined confounders age, GCS, pupil reactivity, hematoma size and  
632 midline shift, was used to estimate acute surgery preference per centre with corresponding 95% CIs.

634 (B) The colour coding in this geographical representation of Europe depicts the log odds of acute  
635 surgery per country compared with the overall average, adjusted for confounding, by means of the  
636 same model used for the centre analysis.

637

638 **Figure 3: Subgroup analyses of the primary outcome for acute surgery, on patient-level.**

639 The panel shows the common odds ratio for an improvement on the ordinal Glasgow Outcome Scale  
640 Extended for acute surgery, stratified for subgroups, using ordinal logistic regressions with random-effects adjusted for predefined confounders. Baseline prognosis is summarized in the mean CRASH-  
641 CT predicted 6-month unfavourable outcome ( $GOS \leq 3$ , %).

642

## Supplementary appendix

### Table of contents

1. **The CENTER-TBI participants and investigators (page 2-11)**
2. **Additional methods (page 12-14)**
3. **Additional results (page 15)**
4. **Supplemental tables and figures (page 16-41)**

**Supplemental Figure 1.** Sliding scale representation of clinical decision and consequential study population.

**Supplemental Table 1.** Baseline and treatment characteristics of patients with traumatic ASDH, comparing acute surgical evacuation, conservative treatment and no treatment

**Supplemental Table 2.** Baseline and hospital characteristics of non-salvageable patients

**Supplemental Figure 2.** Motivations for acute surgery, conservative treatment, and secondary surgery after initial conservative treatment

**Supplemental Table 3.** Baseline characteristics of the cohort for the post-hoc analysis, across centres with different preferences for immediate treatment of acute subdural hematoma

**Supplemental Figure 3.** Proportions per centre with acute surgery of all ASDH patients

**Supplemental Table 4.** Assumptions for instrumental variable analysis

**Supplemental Figure 4.** Functional outcome with centres with different rates of acute surgery

**Supplemental Table 5.** Primary and secondary outcomes and association with acute surgery of the post-hoc analysis

**Supplemental Figure 5.** Subgroup analyses for acute surgery in the instrumental variable cohort

**Supplemental Table 6.** Results of sensitivity analyses: comparing analytical methods to adjust for confounding by indication

**Supplemental Table 7.** Baseline characteristics of propensity matched cohort, comparing acute surgical evacuation with conservative treatment

**Supplemental Figure 6.** Propensity scores distribution of nonmatched cohorts and propensity matched cohorts of acute surgery

**Supplemental Table 8.** Hospital course and outcomes

5. **Search string panel (page 42-49)**
6. **References (page 50)**

## 1. The CENTER-TBI participants and investigators

Cecilia Åkerlund<sup>1</sup>, Krisztina Amrein<sup>2</sup>, Nada Andelic<sup>3</sup>, Lasse Andreassen<sup>4</sup>, Audny Anke<sup>5</sup>, Anna Antoni<sup>6</sup>, Gérard Audibert<sup>7</sup>, Philippe Azouvi<sup>8</sup>, Maria Luisa Azzolini<sup>9</sup>, Ronald Bartels<sup>10</sup>, Pál Barzó<sup>11</sup>, Romuald Beauvais<sup>12</sup>, Ronny Beer<sup>13</sup>, Bo-Michael Bellander<sup>14</sup>, Antonio Belli<sup>15</sup>, Habib Benali<sup>16</sup>, Maurizio Berardino<sup>17</sup>, Luigi Beretta<sup>9</sup>, Morten Blaabjerg<sup>18</sup>, Peter Bragge<sup>19</sup>, Alexandra Brazinova<sup>20</sup>, Vibeke Brinck<sup>21</sup>, Joanne Brooker<sup>22</sup>, Camilla Brorsson<sup>23</sup>, Andras Buki<sup>24</sup>, Monika Bullinger<sup>25</sup>, Manuel Cabeleira<sup>26</sup>, Alessio Caccioppola<sup>27</sup>, Emiliana Calappi<sup>27</sup>, Maria Rosa Calvi<sup>9</sup>, Peter Cameron<sup>28</sup>, Guillermo Carbayo Lozano<sup>29</sup>, Marco Carbonara<sup>27</sup>, Simona Cavallo<sup>17</sup>, Giorgio Chevallard<sup>30</sup>, Arturo Chieregato<sup>30</sup>, Giuseppe Citerio<sup>31, 32</sup>, Hans Clusmann<sup>33</sup>, Mark Coburn<sup>34</sup>, Jonathan Coles<sup>35</sup>, Jamie D. Cooper<sup>36</sup>, Marta Correia<sup>37</sup>, Amra Čović<sup>38</sup>, Nicola Curry<sup>39</sup>, Endre Czeiter<sup>24</sup>, Marek Czosnyka<sup>26</sup>, Claire Dahyot-Fizelier<sup>40</sup>, Paul Dark<sup>41</sup>, Helen Dawes<sup>42</sup>, Véronique De Keyser<sup>43</sup>, Vincent Degos<sup>16</sup>, Francesco Della Corte<sup>44</sup>, Hugo den Boogert<sup>10</sup>, Bart Depreitere<sup>45</sup>, Đula Đilvesi<sup>46</sup>, Abhishek Dixit<sup>47</sup>, Emma Donoghue<sup>22</sup>, Jens Dreier<sup>48</sup>, Guy-Loup Dulière<sup>49</sup>, Ari Ercole<sup>47</sup>, Patrick Esser<sup>42</sup>, Erzsébet Ezer<sup>50</sup>, Martin Fabricius<sup>51</sup>, Valery L. Feigin<sup>52</sup>, Kelly Foks<sup>53</sup>, Shirin Frisvold<sup>54</sup>, Alex Furmanov<sup>55</sup>, Pablo Gagliardo<sup>56</sup>, Damien Galanaud<sup>16</sup>, Dashiell Gantner<sup>28</sup>, Guoyi Gao<sup>57</sup>, Pradeep George<sup>58</sup>, Alexandre Ghuyssen<sup>59</sup>, Lelde Giga<sup>60</sup>, Ben Glocker<sup>61</sup>, Jagoš Golubovic<sup>46</sup>, Pedro A. Gomez<sup>62</sup>, Johannes Gratz<sup>63</sup>, Benjamin Gravesteijn<sup>64</sup>, Francesca Grossi<sup>44</sup>, Russell L. Gruen<sup>65</sup>, Deepak Gupta<sup>66</sup>, Juanita A. Haagsma<sup>64</sup>, Iain Haitsma<sup>67</sup>, Raimund Helbok<sup>13</sup>, Eirik Helseth<sup>68</sup>, Lindsay Horton<sup>69</sup>, Jilske Huijben<sup>64</sup>, Peter J. Hutchinson<sup>70</sup>, Bram Jacobs<sup>71</sup>, Stefan Jankowski<sup>72</sup>, Mike Jarrett<sup>21</sup>, Ji-yao Jiang<sup>58</sup>, Faye Johnson<sup>73</sup>, Kelly Jones<sup>52</sup>, Mladen Karan<sup>46</sup>, Angelos G. Kolias<sup>70</sup>, Erwin Kompanje<sup>74</sup>, Daniel Kondziella<sup>51</sup>, Evgenios Kornaropoulos<sup>47</sup>, Lars-Owe Koskinen<sup>75</sup>, Noémi Kovács<sup>76</sup>, Ana Kowark<sup>77</sup>, Alfonso Lagares<sup>62</sup>, Linda Lanyon<sup>58</sup>, Steven Laureys<sup>78</sup>, Fiona Lecky<sup>79, 80</sup>, Didier Ledoux<sup>78</sup>, Rolf Lefering<sup>81</sup>, Valerie Legrand<sup>82</sup>, Aurelie Lejeune<sup>83</sup>, Leon Levi<sup>84</sup>, Roger Lightfoot<sup>85</sup>, Hester Lingsma<sup>64</sup>, Andrew I.R. Maas<sup>43</sup>, Ana M. Castaño-León<sup>62</sup>, Marc Maegele<sup>86</sup>, Marek Majdan<sup>20</sup>, Alex Manara<sup>87</sup>, Geoffrey Manley<sup>88</sup>, Costanza Martino<sup>89</sup>, Hugues Maréchal<sup>49</sup>, Julia Mattern<sup>90</sup>, Catherine McMahon<sup>91</sup>, Béla Meleghe<sup>92</sup>, David Menon<sup>47</sup>, Tomas Menovsky<sup>43</sup>, Ana Mikolic<sup>64</sup>, Benoit Misset<sup>78</sup>, Visakh Muraleedharan<sup>58</sup>, Lynnette Murray<sup>28</sup>, Ancuta Negru<sup>93</sup>, David Nelson<sup>1</sup>, Virginia Newcombe<sup>47</sup>, Daan Nieboer<sup>64</sup>, József Nyírádi<sup>2</sup>, Otesile Olubukola<sup>79</sup>, Matej Oresic<sup>94</sup>, Fabrizio Ortolano<sup>27</sup>, Aarno Palotie<sup>95, 96, 97</sup>, Paul M. Parizel<sup>98</sup>, Jean-François Payen<sup>99</sup>, Natascha Perera<sup>12</sup>, Vincent Perlberg<sup>16</sup>, Paolo Persona<sup>100</sup>, Wilco Peul<sup>101</sup>, Anna Piippo-Karjalainen<sup>102</sup>, Matti Pirinen<sup>95</sup>, Dana Pisica<sup>64</sup>, Horia Ples<sup>93</sup>, Suzanne Polinder<sup>64</sup>, Inigo Pomposo<sup>29</sup>, Jussi P. Posti<sup>103</sup>, Louis Puybasset<sup>104</sup>, Andreea Radoi<sup>105</sup>, Arminas Ragauskas<sup>106</sup>, Rahul Raj<sup>102</sup>, Malinka Rambadagalla<sup>107</sup>, Isabel Retel Helmrich<sup>64</sup>, Jonathan Rhodes<sup>108</sup>, Sylvia Richardson<sup>109</sup>, Sophie Richter<sup>47</sup>, Samuli Ripatti<sup>95</sup>, Saulius Rocka<sup>106</sup>, Cecilie Roe<sup>110</sup>, Olav Roise<sup>111, 112</sup>, Jonathan Rosand<sup>113</sup>, Jeffrey V. Rosenfeld<sup>114</sup>, Christina Rosenlund<sup>115</sup>, Guy Rosenthal<sup>55</sup>, Rolf Rossaint<sup>77</sup>, Sandra Rossi<sup>100</sup>, Daniel Rueckert<sup>61</sup>, Martin Rusnák<sup>116</sup>, Juan Sahuquillo<sup>105</sup>, Oliver Sakowitz<sup>90, 117</sup>, Renan Sanchez-Porras<sup>117</sup>, Janos Sandor<sup>118</sup>, Nadine Schäfer<sup>81</sup>, Silke Schmidt<sup>119</sup>, Herbert Schoechl<sup>120</sup>, Guus Schoonman<sup>121</sup>, Rico Frederik Schou<sup>122</sup>, Elisabeth Schwendenwein<sup>6</sup>, Charlie Sewalt<sup>64</sup>, Toril Skandsen<sup>123, 124</sup>, Peter Smielewski<sup>26</sup>, Abayomi Sorinola<sup>125</sup>, Emmanuel Stamatakis<sup>47</sup>, Simon Stanworth<sup>39</sup>, Robert Stevens<sup>126</sup>, William Stewart<sup>127</sup>, Ewout W. Steyerberg<sup>64, 128</sup>, Nino Stocchetti<sup>129</sup>, Nina Sundström<sup>130</sup>, Riikka Takala<sup>131</sup>, Viktória Tamás<sup>125</sup>, Tomas Tamosuitis<sup>132</sup>, Mark Steven Taylor<sup>20</sup>, Braden Te Ao<sup>52</sup>, Olli Tenovuo<sup>103</sup>, Alice Theadom<sup>52</sup>, Matt Thomas<sup>87</sup>, Dick Tibboel<sup>133</sup>, Marjolein Timmers<sup>74</sup>, Christos Tolia<sup>134</sup>, Tony Trapani<sup>28</sup>, Cristina Maria Tudora<sup>93</sup>, Andreas Unterberg<sup>90</sup>, Peter Vajkoczy<sup>135</sup>, Shirley Vallance<sup>28</sup>, Egils Valeinis<sup>60</sup>, Zoltán Vámos<sup>50</sup>, Mathieu van der Jagt<sup>136</sup>, Gregory Van der Steen<sup>43</sup>, Joukje van der Naalt<sup>71</sup>, Jeroen T.J.M. van Dijck<sup>101</sup>, Thomas A. van Essen<sup>101</sup>, Wim Van Hecke<sup>137</sup>, Caroline van Heugten<sup>138</sup>, Dominique Van Praag<sup>139</sup>, Ernest van Veen<sup>64</sup>, Thijs Vande Vyvere<sup>137</sup>, Roel P. J. van Wijk<sup>101</sup>, Alessia Vargiolu<sup>32</sup>, Emmanuel Vega<sup>83</sup>, Kimberley Velt<sup>64</sup>, Jan Verheyden<sup>137</sup>, Paul M. Vespa<sup>140</sup>, Anne Vik<sup>123, 141</sup>, Rimantas Vilcinis<sup>132</sup>, Victor Volovici<sup>67</sup>, Nicole von Steinbüchel<sup>38</sup>, Daphne Voormolen<sup>64</sup>, Petar Vulekovic<sup>46</sup>, Kevin K.W. Wang<sup>142</sup>, Eveline Wieggers<sup>64</sup>, Guy Williams<sup>47</sup>, Lindsay Wilson<sup>69</sup>, Stefan Winzeck<sup>47</sup>, Stefan Wolf<sup>143</sup>, Zhihui Yang<sup>113</sup>, Peter Ylén<sup>144</sup>, Alexander Younsi<sup>90</sup>, Frederick A. Zeiler<sup>47, 145</sup>, Veronika Zelinkova<sup>20</sup>, Agate Ziverte<sup>60</sup>, Tommaso Zoerle<sup>27</sup>

- <sup>1</sup> Department of Physiology and Pharmacology, Section of Perioperative Medicine and Intensive Care, Karolinska Institutet, Stockholm, Sweden
- <sup>2</sup> János Szentágothai Research Centre, University of Pécs, Pécs, Hungary
- <sup>3</sup> Division of Surgery and Clinical Neuroscience, Department of Physical Medicine and Rehabilitation, Oslo University Hospital and University of Oslo, Oslo, Norway
- <sup>4</sup> Department of Neurosurgery, University Hospital Northern Norway, Tromsø, Norway
- <sup>5</sup> Department of Physical Medicine and Rehabilitation, University Hospital Northern Norway, Tromsø, Norway
- <sup>6</sup> Trauma Surgery, Medical University Vienna, Vienna, Austria
- <sup>7</sup> Department of Anesthesiology & Intensive Care, University Hospital Nancy, Nancy, France
- <sup>8</sup> Raymond Poincaré hospital, Assistance Publique – Hôpitaux de Paris, Paris, France
- <sup>9</sup> Department of Anesthesiology & Intensive Care, S Raffaele University Hospital, Milan, Italy
- <sup>10</sup> Department of Neurosurgery, Radboud University Medical Centre, Nijmegen, The Netherlands
- <sup>11</sup> Department of Neurosurgery, University of Szeged, Szeged, Hungary
- <sup>12</sup> International Projects Management, ARTTIC, München, Germany
- <sup>13</sup> Department of Neurology, Neurological Intensive Care Unit, Medical University of Innsbruck, Innsbruck, Austria
- <sup>14</sup> Department of Neurosurgery & Anesthesia & intensive care medicine, Karolinska University Hospital, Stockholm, Sweden
- <sup>15</sup> NIHR Surgical Reconstruction and Microbiology Research Centre, Birmingham, UK
- <sup>16</sup> Anesthésie-Réanimation, Assistance Publique – Hôpitaux de Paris, Paris, France
- <sup>17</sup> Department of Anesthesia & ICU, AOU Città della Salute e della Scienza di Torino - Orthopedic and Trauma Center, Torino, Italy
- <sup>18</sup> Department of Neurology, Odense University Hospital, Odense, Denmark
- <sup>19</sup> BehaviourWorks Australia, Monash Sustainability Institute, Monash University, Victoria, Australia
- <sup>20</sup> Department of Public Health, Faculty of Health Sciences and Social Work, Trnava University, Trnava, Slovakia
- <sup>21</sup> Quesgen Systems Inc., Burlingame, California, USA
- <sup>22</sup> Australian & New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
- <sup>23</sup> Department of Surgery and Perioperative Science, Umeå University, Umeå, Sweden
- <sup>24</sup> Department of Neurosurgery, Medical School, University of Pécs, Hungary and Neurotrauma Research Group, János Szentágothai Research Centre, University of Pécs, Hungary
- <sup>25</sup> Department of Medical Psychology, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
- <sup>26</sup> Brain Physics Lab, Division of Neurosurgery, Dept of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
- <sup>27</sup> Neuro ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
- <sup>28</sup> ANZIC Research Centre, Monash University, Department of Epidemiology and Preventive Medicine, Melbourne, Victoria, Australia
- <sup>29</sup> Department of Neurosurgery, Hospital of Cruces, Bilbao, Spain
- <sup>30</sup> NeuroIntensive Care, Niguarda Hospital, Milan, Italy
- <sup>31</sup> School of Medicine and Surgery, Università Milano Bicocca, Milano, Italy
- <sup>32</sup> NeuroIntensive Care, ASST di Monza, Monza, Italy
- <sup>33</sup> Department of Neurosurgery, Medical Faculty RWTH Aachen University, Aachen, Germany
- <sup>34</sup> Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany
- <sup>35</sup> Department of Anesthesia & Neurointensive Care, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK
- <sup>36</sup> School of Public Health & PM, Monash University and The Alfred Hospital, Melbourne, Victoria, Australia
- <sup>37</sup> Radiology/MRI department, MRC Cognition and Brain Sciences Unit, Cambridge, UK
- <sup>38</sup> Institute of Medical Psychology and Medical Sociology, Universitätsmedizin Göttingen, Göttingen, Germany
- <sup>39</sup> Oxford University Hospitals NHS Trust, Oxford, UK
- <sup>40</sup> Intensive Care Unit, CHU Poitiers, Poitiers, France
- <sup>41</sup> University of Manchester NIHR Biomedical Research Centre, Critical Care Directorate, Salford Royal Hospital NHS Foundation Trust, Salford, UK
- <sup>42</sup> Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, UK
- <sup>43</sup> Department of Neurosurgery, Antwerp University Hospital and University of Antwerp, Edegem, Belgium
- <sup>44</sup> Department of Anesthesia & Intensive Care, Maggiore Della Carità Hospital, Novara, Italy
- <sup>45</sup> Department of Neurosurgery, University Hospitals Leuven, Leuven, Belgium
- <sup>46</sup> Department of Neurosurgery, Clinical centre of Vojvodina, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
- <sup>47</sup> Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK

- <sup>48</sup> Center for Stroke Research Berlin, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- <sup>49</sup> Intensive Care Unit, CHR Citadelle, Liège, Belgium
- <sup>50</sup> Department of Anaesthesiology and Intensive Therapy, University of Pécs, Pécs, Hungary
- <sup>51</sup> Departments of Neurology, Clinical Neurophysiology and Neuroanesthesiology, Region Hovedstaden Rigshospitalet, Copenhagen, Denmark
- <sup>52</sup> National Institute for Stroke and Applied Neurosciences, Faculty of Health and Environmental Studies, Auckland University of Technology, Auckland, New Zealand
- <sup>53</sup> Department of Neurology, Erasmus MC, Rotterdam, the Netherlands
- <sup>54</sup> Department of Anesthesiology and Intensive care, University Hospital Northern Norway, Tromsø, Norway
- <sup>55</sup> Department of Neurosurgery, Hadassah-hebrew University Medical center, Jerusalem, Israel
- <sup>56</sup> Fundación Instituto Valenciano de Neurorehabilitación (FIVAN), Valencia, Spain
- <sup>57</sup> Department of Neurosurgery, Shanghai Renji hospital, Shanghai Jiaotong University/school of medicine, Shanghai, China
- <sup>58</sup> Karolinska Institutet, INCF International Neuroinformatics Coordinating Facility, Stockholm, Sweden
- <sup>59</sup> Emergency Department, CHU, Liège, Belgium
- <sup>60</sup> Neurosurgery clinic, Pauls Stradins Clinical University Hospital, Riga, Latvia
- <sup>61</sup> Department of Computing, Imperial College London, London, UK
- <sup>62</sup> Department of Neurosurgery, Hospital Universitario 12 de Octubre, Madrid, Spain
- <sup>63</sup> Department of Anesthesia, Critical Care and Pain Medicine, Medical University of Vienna, Austria
- <sup>64</sup> Department of Public Health, Erasmus Medical Centre-University Medical Centre, Rotterdam, The Netherlands
- <sup>65</sup> College of Health and Medicine, Australian National University, Canberra, Australia
- <sup>66</sup> Department of Neurosurgery, Neurosciences Centre & JPN Apex trauma centre, All India Institute of Medical Sciences, New Delhi-110029, India
- <sup>67</sup> Department of Neurosurgery, Erasmus MC, Rotterdam, the Netherlands
- <sup>68</sup> Department of Neurosurgery, Oslo University Hospital, Oslo, Norway
- <sup>69</sup> Division of Psychology, University of Stirling, Stirling, UK
- <sup>70</sup> Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's Hospital & University of Cambridge, Cambridge, UK
- <sup>71</sup> Department of Neurology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands
- <sup>72</sup> Neurointensive Care , Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
- <sup>73</sup> Salford Royal Hospital NHS Foundation Trust Acute Research Delivery Team, Salford, UK
- <sup>74</sup> Department of Intensive Care and Department of Ethics and Philosophy of Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
- <sup>75</sup> Department of Clinical Neuroscience, Neurosurgery, Umeå University, Umeå, Sweden
- <sup>76</sup> Hungarian Brain Research Program - Grant No. KTIA\_13\_NAP-A-II/8, University of Pécs, Pécs, Hungary
- <sup>77</sup> Department of Anaesthesiology, University Hospital of Aachen, Aachen, Germany
- <sup>78</sup> Cyclotron Research Center , University of Liège, Liège, Belgium
- <sup>79</sup> Centre for Urgent and Emergency Care Research (CURE), Health Services Research Section, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
- <sup>80</sup> Emergency Department, Salford Royal Hospital, Salford UK
- <sup>81</sup> Institute of Research in Operative Medicine (IFOM), Witten/Herdecke University, Cologne, Germany
- <sup>82</sup> VP Global Project Management CNS, ICON, Paris, France
- <sup>83</sup> Department of Anesthesiology-Intensive Care, Lille University Hospital, Lille, France
- <sup>84</sup> Department of Neurosurgery, Rambam Medical Center, Haifa, Israel
- <sup>85</sup> Department of Anesthesiology & Intensive Care, University Hospitals Southampton NHS Trust, Southampton, UK
- <sup>86</sup> Cologne-Merheim Medical Center (CMMC), Department of Traumatology, Orthopedic Surgery and Sportmedicine, Witten/Herdecke University, Cologne, Germany
- <sup>87</sup> Intensive Care Unit, Southmead Hospital, Bristol, Bristol, UK
- <sup>88</sup> Department of Neurological Surgery, University of California, San Francisco, California, USA
- <sup>89</sup> Department of Anesthesia & Intensive Care, M. Bufalini Hospital, Cesena, Italy
- <sup>90</sup> Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany
- <sup>91</sup> Department of Neurosurgery, The Walton centre NHS Foundation Trust, Liverpool, UK
- <sup>92</sup> Department of Medical Genetics, University of Pécs, Pécs, Hungary
- <sup>93</sup> Department of Neurosurgery, Emergency County Hospital Timisoara , Timisoara, Romania
- <sup>94</sup> School of Medical Sciences, Örebro University, Örebro, Sweden
- <sup>95</sup> Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland



- <sup>96</sup> Analytic and Translational Genetics Unit, Department of Medicine; Psychiatric & Neurodevelopmental Genetics Unit, Department of Psychiatry; Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
- <sup>97</sup> Program in Medical and Population Genetics; The Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, Cambridge, MA, USA
- <sup>98</sup> Department of Radiology, University of Antwerp, Edegem, Belgium
- <sup>99</sup> Department of Anesthesiology & Intensive Care, University Hospital of Grenoble, Grenoble, France
- <sup>100</sup> Department of Anesthesia & Intensive Care, Azienda Ospedaliera Università di Padova, Padova, Italy
- <sup>101</sup> Dept. of Neurosurgery, Leiden University Medical Centre, Leiden, The Netherlands and Dept. of Neurosurgery, Medical Centre Haaglanden, The Hague, The Netherlands
- <sup>102</sup> Department of Neurosurgery, Helsinki University Central Hospital
- <sup>103</sup> Division of Clinical Neurosciences, Department of Neurosurgery and Turku Brain Injury Centre, Turku University Hospital and University of Turku, Turku, Finland
- <sup>104</sup> Department of Anesthesiology and Critical Care, Pitié -Salpêtrière Teaching Hospital, Assistance Publique, Hôpitaux de Paris and University Pierre et Marie Curie, Paris, France
- <sup>105</sup> Neurotraumatology and Neurosurgery Research Unit (UNINN), Vall d'Hebron Research Institute, Barcelona, Spain
- <sup>106</sup> Department of Neurosurgery, Kaunas University of technology and Vilnius University, Vilnius, Lithuania
- <sup>107</sup> Department of Neurosurgery, Rezekne Hospital, Latvia
- <sup>108</sup> Department of Anaesthesia, Critical Care & Pain Medicine NHS Lothian & University of Edinburgh, Edinburgh, UK
- <sup>109</sup> Director, MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, UK
- <sup>110</sup> Department of Physical Medicine and Rehabilitation, Oslo University Hospital/University of Oslo, Oslo, Norway
- <sup>111</sup> Division of Orthopedics, Oslo University Hospital, Oslo, Norway
- <sup>112</sup> Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
- <sup>113</sup> Broad Institute, Cambridge MA Harvard Medical School, Boston MA, Massachusetts General Hospital, Boston MA, USA
- <sup>114</sup> National Trauma Research Institute, The Alfred Hospital, Monash University, Melbourne, Victoria, Australia
- <sup>115</sup> Department of Neurosurgery, Odense University Hospital, Odense, Denmark
- <sup>116</sup> International Neurotrauma Research Organisation, Vienna, Austria
- <sup>117</sup> Klinik für Neurochirurgie, Klinikum Ludwigsburg, Ludwigsburg, Germany
- <sup>118</sup> Division of Biostatistics and Epidemiology, Department of Preventive Medicine, University of Debrecen, Debrecen, Hungary
- <sup>119</sup> Department Health and Prevention, University Greifswald, Greifswald, Germany
- <sup>120</sup> Department of Anaesthesiology and Intensive Care, AUVA Trauma Hospital, Salzburg, Austria
- <sup>121</sup> Department of Neurology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, the Netherlands
- <sup>122</sup> Department of Neuroanesthesia and Neurointensive Care, Odense University Hospital, Odense, Denmark
- <sup>123</sup> Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, NTNU, Trondheim, Norway
- <sup>124</sup> Department of Physical Medicine and Rehabilitation, St.Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
- <sup>125</sup> Department of Neurosurgery, University of Pécs, Pécs, Hungary
- <sup>126</sup> Division of Neuroscience Critical Care, John Hopkins University School of Medicine, Baltimore, USA
- <sup>127</sup> Department of Neuropathology, Queen Elizabeth University Hospital and University of Glasgow, Glasgow, UK
- <sup>128</sup> Dept. of Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, The Netherlands
- <sup>129</sup> Department of Pathophysiology and Transplantation, Milan University, and Neuroscience ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy
- <sup>130</sup> Department of Radiation Sciences, Biomedical Engineering, Umeå University, Umeå, Sweden
- <sup>131</sup> Perioperative Services, Intensive Care Medicine and Pain Management, Turku University Hospital and University of Turku, Turku, Finland
- <sup>132</sup> Department of Neurosurgery, Kaunas University of Health Sciences, Kaunas, Lithuania
- <sup>133</sup> Intensive Care and Department of Pediatric Surgery, Erasmus Medical Centre, Sophia Children's Hospital, Rotterdam, The Netherlands
- <sup>134</sup> Department of Neurosurgery, Kings college London, London, UK
- <sup>135</sup> Neurologie, Neurochirurgie und Psychiatrie, Charité – Universitätsmedizin Berlin, Berlin, Germany
- <sup>136</sup> Department of Intensive Care Adults, Erasmus MC– University Medical Centre Rotterdam, Rotterdam, the Netherlands

<sup>137</sup> icoMetrix NV, Leuven, Belgium

<sup>138</sup> Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, UK

<sup>139</sup> Psychology Department, Antwerp University Hospital, Edegem, Belgium

<sup>140</sup> Director of Neurocritical Care, University of California, Los Angeles, USA

<sup>141</sup> Department of Neurosurgery, St.Olavs Hospital, Trondheim University Hospital, Trondheim, Norway

<sup>142</sup> Department of Emergency Medicine, University of Florida, Gainesville, Florida, USA

<sup>143</sup> Department of Neurosurgery, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

<sup>144</sup> VTT Technical Research Centre, Tampere, Finland

<sup>145</sup> Section of Neurosurgery, Department of Surgery, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada

Åkerlund	Cecilia	cecilia.ai.akerlund@gmail.com
Amrein	Krisztina	tina.amrein84@gmail.com
Andelic	Nada	NADAND@ous-hf.no
Andreassen	Lasse	Lasse.Andreassen@unn.no
Anke	Audny	Audny.anke@unn.no
Antoni	Anna	anna.antoni@meduniwien.ac.at
Audibert	Gérard	g.audibert@chu-nancy.fr
Azouvi	Philippe	philippe.azouvi@rpc.aphp.fr
Azzolini	Maria Luisa	azzolini.marialuisa@hsr.it
Bartels	Ronald	Ronald.Bartels@radboudumc.nl
Barzó	Pál	pbarzo@gmail.com
Beauvais	Romuald	beauvais@artic.eu
Beer	Ronny	ronny.beer@i-med.ac.at
Bellander	Bo-Michael	bo-michael.bellander@karolinska.se
Belli	Antonio	a.belli@bham.ac.uk
Benali	Habib	habib.benali@gmail.com
Berardino	Maurizio	maurizio_berardino@fastwebnet.it
Beretta	Luigi	beretta.luigi@hsr.it
Blaabjerg	Morten	morten.blaabjerg1@rsyd.dk
Bragge	Peter	peter.bragge@monash.edu
Brazinova	Alexandra	alexandra.brazinova@gmail.com
Brinck	Vibeke	vibeke.brinck@quesgen.com
Brooker	Joanne	Joanne.Brooker@monash.edu
Brorsson	Camilla	Camilla.Brorsson@umu.se
Buki	Andras	2saturn@gmail.com
Bullinger	Monika	bullinger@uke.de
Cabeleira	Manuel	mc916@cam.ac.uk
Caccioppola	Alessio	alessio.caccioppola@gmail.com
Calappi	Emiliana	calemy02@yahoo.it
Calvi	Maria Rosa	calvi.mariarosa@hsr.it
Cameron	Peter	peter.cameron@med.monash.edu.au
Carbayo Lozano	Guillermo	guillermobilbo@gmail.com
Carbonara	Marco	marco.carbonara@gmail.com
Castaña-León	Ana M.	ana.maria.castano.leon@gmail.com
Cavallo	Simona	cavallosimona1@gmail.com
Chevallard	Giorgio	giorgio.chevallard@ospedaleniguarda.it

Chieregato	Arturo	<a href="mailto:arturo.chieregato@ospedaleniguarda.it">arturo.chieregato@ospedaleniguarda.it</a>
Citerio	Giuseppe	<a href="mailto:giuseppe.citerio@unimib.it">giuseppe.citerio@unimib.it</a>
Clusmann	Hans	<a href="mailto:hclusmann@ukaachen.de">hclusmann@ukaachen.de</a>
Coburn	Mark Steven	<a href="mailto:mark.coburn@ukbonn.de">mark.coburn@ukbonn.de</a>
Coles	Jonathan	<a href="mailto:jpc44@wbic.cam.ac.uk">jpc44@wbic.cam.ac.uk</a>
Cooper	Jamie D.	<a href="mailto:jamie.cooper@monash.edu">jamie.cooper@monash.edu</a>
Correia	Marta	<a href="mailto:Marta.Correia@mrc-cbu.cam.ac.uk">Marta.Correia@mrc-cbu.cam.ac.uk</a>
Čović	Amra	<a href="mailto:amra.covic@med.uni-goettingen.de">amra.covic@med.uni-goettingen.de</a>
Curry	Nicola	<a href="mailto:nicola.curry@ouh.nhs.uk">nicola.curry@ouh.nhs.uk</a>
Czeiter	Endre	<a href="mailto:endre.czeiter@gmail.com">endre.czeiter@gmail.com</a>
Czosnyka	Marek	<a href="mailto:mc141@medschl.cam.ac.uk">mc141@medschl.cam.ac.uk</a>
Dahyot-Fizelier	Claire	<a href="mailto:c.dahyot-fizelier@chu-poitiers.fr">c.dahyot-fizelier@chu-poitiers.fr</a>
Dark	Paul	<a href="mailto:paul.m.dark@manchester.ac.uk">paul.m.dark@manchester.ac.uk</a>
Dawes	Helen	<a href="mailto:hdawes@brookes.ac.uk">hdawes@brookes.ac.uk</a>
De Keyser	Véronique	<a href="mailto:veronique.dekeyser@uza.be">veronique.dekeyser@uza.be</a>
Degos	Vincent	<a href="mailto:vincent.degos@aphp.fr">vincent.degos@aphp.fr</a>
Della Corte	Francesco	<a href="mailto:dellacorte.f@gmail.com">dellacorte.f@gmail.com</a>
den Boogert	Hugo	<a href="mailto:Hugo.denBoogert@radboudumc.nl">Hugo.denBoogert@radboudumc.nl</a>
Depreitere	Bart	<a href="mailto:bart.depreitere@uzleuven.be">bart.depreitere@uzleuven.be</a>
Đilvesi	Đula	<a href="mailto:djuladilvesi@gmail.com">djuladilvesi@gmail.com</a>
Dixit	Abhishek	<a href="mailto:ad825@cam.ac.uk">ad825@cam.ac.uk</a>
Donoghue	Emma	<a href="mailto:emma.donoghue@monash.edu">emma.donoghue@monash.edu</a>
Dreier	Jens	<a href="mailto:jens.dreier@charite.de">jens.dreier@charite.de</a>
Dulière	Guy-Loup	<a href="mailto:glduliere@gmail.com">glduliere@gmail.com</a>
Ercole	Ari	<a href="mailto:ae105@cam.ac.uk">ae105@cam.ac.uk</a>
Esser	Patrick	<a href="mailto:pesser@brookes.ac.uk">pesser@brookes.ac.uk</a>
Ezer	Erzsébet	<a href="mailto:ezererzsebet@yahoo.com">ezererzsebet@yahoo.com</a>
Fabricius	Martin	<a href="mailto:fabricius@dadlnet.dk">fabricius@dadlnet.dk</a>
Feigin	Valery L.	<a href="mailto:valery.feigin@aut.ac.nz">valery.feigin@aut.ac.nz</a>
Foks	Kelly	<a href="mailto:k.foks@erasmusmc.nl">k.foks@erasmusmc.nl</a>
Frisvold	Shirin	<a href="mailto:Shirin.Kordasti@unn.no">Shirin.Kordasti@unn.no</a>
Furmanov	Alex	<a href="mailto:alexpuil@yahoo.com">alexpuil@yahoo.com</a>
Gagliardo	Pablo	<a href="mailto:pablog@fivan.org">pablog@fivan.org</a>
Galanaud	Damien	<a href="mailto:galanaud@gmail.com">galanaud@gmail.com</a>
Gantner	Dashiell	<a href="mailto:dashiell.gantner@monash.edu">dashiell.gantner@monash.edu</a>
Gao	Guoyi	<a href="mailto:gao3@sina.com">gao3@sina.com</a>
George	Pradeep	<a href="mailto:george@incf.org">george@incf.org</a>
Ghuysen	Alexandre	<a href="mailto:A.Ghuysen@chu.ulg.ac.be">A.Ghuysen@chu.ulg.ac.be</a>
Giga	Lelde	<a href="mailto:lelde.giga@inbox.lv">lelde.giga@inbox.lv</a>
Glocker	Ben	<a href="mailto:b.glocker@imperial.ac.uk">b.glocker@imperial.ac.uk</a>
Golubović	Jagoš	<a href="mailto:jagogolubovic@gmail.com">jagogolubovic@gmail.com</a>
Gomez	Pedro A.	<a href="mailto:pagolopez@gmail.com">pagolopez@gmail.com</a>
Gratz	Johannes	<a href="mailto:johannes.gratz@meduniwien.ac.at">johannes.gratz@meduniwien.ac.at</a>
Gravestijn	Benjamin	<a href="mailto:b.gravestijn@erasmusmc.nl">b.gravestijn@erasmusmc.nl</a>
Grossi	Francesca	<a href="mailto:francesca.grossi@libero.it">francesca.grossi@libero.it</a>
Gruen	Russell L.	<a href="mailto:russell.gruen@anu.edu.au">russell.gruen@anu.edu.au</a>

Gupta	Deepak	drdeepakgupta@gmail.com
Haagsma	Juanita A.	j.haagsma@erasmusmc.nl
Haitsma	Iain	i.haitsma@erasmusmc.nl
Helbok	Raimund	Raimund.Helbok@tirol-kliniken.at
Helseth	Eirik	EHELSETH@ous-hf.no
Horton	Lindsay	lindsay.horton@stir.ac.uk
Huijben	Jilske	j.a.huijben@erasmusmc.nl
Hutchinson	Peter J.	pjah2@cam.ac.uk
Jacobs	Bram	b.jacobs@umcg.nl
Jankowski	Stefan	Stefan.Jankowski@sth.nhs.uk
Jarrett	Mike	mike.jarrett@quesgen.com
Jiang	Ji-yao	jiyaojiang@126.com
Johnson	Faye	faye.johnson@live.co.uk
Jones	Kelly	kejones@aut.ac.nz
Karan	Mladen	mladjokaran@gmail.com
Kolias	Angelos G.	angeloskolias@gmail.com
Kompanje	Erwin	erwinkompanje@me.com
Kondziella	Daniel	Daniel.Kondziella@regionh.dk
Kornaropoulos	Evgenios	ek481@cam.ac.uk
Koskinen	Lars-Owe	Lars-Owe.Koskinen@umu.se
Kovács	Noémi	kovacs.noemi@pte.hu
Lagares	Alfonso	algadoc@yahoo.com
Lanyon	Linda	lindal@incf.org
Laureys	Steven	steven.laureys@ulg.ac.be
Lecky	Fiona	f.e.lecky@sheffield.ac.uk
Ledoux	Didier	dledoux@chu.ulg.ac.be
Lefering	Rolf	Rolf.Lefering@uni-wh.de
Legrand	Valerie	Valerie.Legrand@iconplc.com
Lejeune	Aurelie	aurelie.lejeune@chru-lille.fr
Levi	Leon	llevi@rambam.health.gov.il
Lightfoot	Roger	Roger.Lightfoot@uhs.nhs.uk
Lingsma	Hester	h.lingsma@erasmusmc.nl
Maas	Andrew I.R.	andrew.maas@uza.be
Maegele	Marc	Marc.Maegele@t-online.de
Majdan	Marek	mmajdan@truni.sk
Manara	Alex	Alex.Manara@nbt.nhs.uk
Manley	Geoffrey	ManleyG@ucsf.edu
Maréchal	Hugues	Hugues.Marechal@chrcitadelle.be
Martino	Costanza	costmartino74@gmail.com
Mattern	Julia	Julia.Mattern@med.uni-heidelberg.de
McMahon	Catherine	Catherine.McMahon@thewaltoncentre.nhs.uk
Melegh	Béla	bela.melegh@aok.pte.hu
Menon	David	dkm13@cam.ac.uk
Menovsky	Tomas	tomas.menovsky@uza.be
Mikolic	Ana	a.mikolic@erasmusmc.nl
Misset	Benoit	Benoit.Misset@chuliege.be

Muraleedharan	Visakh	visakh@incf.org
Murray	Lynnette	lynnette.murray@monash.edu
Nair	Nandesh	nandesh.nair@uza.be
Negru	Ancuta	negruancu@gmail.com
Nelson	David	david.nelson@karolinska.se
Newcombe	Virginia	vfjn2@cam.ac.uk
Nieboer	Daan	d.nieboer@erasmusmc.nl
Nyirádi	József	nyiradi.jozsef@pte.hu
Oresic	Matej	matej.oresic@oru.se
Ortolano	Fabrizio	lupeda@gmail.com
Otesile	Olubukola	o.otesile@sheffield.ac.uk
Palotie	Aarno	aarno.palotie@helsinki.fi
Parizel	Paul M.	paul.parizel@uantwerpen.be
Payen	Jean-François	Jean-Francois.Payen@ujf-grenoble.fr
Perera	Natascha	perera@arttic.eu
Perlberg	Vincent	vincent.perlberg@gmail.com
Persona	Paolo	ppersona75@gmail.com
Peul	Wilco	W.C.Peul@lumc.nl
Piippo-Karjalainen	Anna	anna.piippo@hus.fi
Pirinen	Matti	matti.pirinen@helsinki.fi
Pisica	Dana	d.pisica@erasmusmc.nl
Ples	Horia	horia.ples@neuromed.ro
Polinder	Suzanne	s.polinder@erasmusmc.nl
Pomposo	Inigo	inigo.pomposo@osakidetza.net
Posti	Jussi P.	jussi.posti@tyks.fi
Puybasset	Louis	louis.puybasset@aphp.fr
Rádoi	Andreea	aradoi@neurotrauma.net
Ragauskas	Arminas	telematics@ktu.lt
Raj	Rahul	rahul.raj@hus.fi
Rambadagalla	Malinka	malinka.rambadagalla@gmail.com
Rehorčíková	Veronika	rehorcikova@gmail.com
Retel Helmrich	Isabel	i.retelhelmrich@erasmusmc.nl
Rhodes	Jonathan	jrhodes1@staffmail.ed.ac.uk
Richardson	Sylvia	sylvia.richardson@mrc-bsu.cam.ac.uk
Richter	Sophie	sr773@cam.ac.uk
Ripatti	Samuli	samuli.ripatti@helsinki.fi
Rocka	Saulius	saulius.rocka@mf.vu.lt
Roe	Cecilie	e.c.t.roe@medisin.uio.no
Roise	Olav	olav.roise@medisin.uio.no
Rosand	Jonathan	jrosand@partners.org
Rosenfeld	Jeffrey	J.Rosenfeld@alfred.org.au
Rosenlund	Christina	chrisstenrose@gmail.com
Rosenthal	Guy	rosenthalg@hadassah.org.il
Rossaint	Rolf	RRossaint@ukaachen.de
Rossi	Sandra	sandrarossi0@gmail.com
Rueckert	Daniel	d.rueckert@imperial.ac.uk

Rusnák	Martin	mrusnak@igeh.org
Sahuquillo	Juan	sahuquillo@neurotrauma.net
Sakowitz	Oliver	oliver.sakowitz@gmail.com
Sanchez-Porras	Renan	renan_md@hotmail.com
Sandor	Janos	sandor.janos@sph.unideb.hu
Schäfer	Nadine	Nadine.Schaefer@uni-wh.de
Schmidt	Silke	silke.schmidt@uni-greifswald.de
Schoechl	Herbert	Herbert.Schoechl@auva.at
Schoonman	Guus	g.schoonman@tsz.nl
Schou	Rico Frederik	rico@mymedic.dk
Schwendenwein	Elisabeth	elisabeth.schwendenwein@meduniwien.ac.at
Sewalt	Charlie	c.sewalt@erasmusmc.nl
Skandsen	Toril	toril.skandsen@ntnu.no
Smielewski	Peter	ps10011@cam.ac.uk
Sorinola	Abayomi	sorinola_abayomi@hotmail.com
Stamatakis	Emmanuel	eas46@cam.ac.uk
Stanworth	Simon	simon.stanworth@nhsbt.nhs.uk
Kowark	Ana	akowark@ukaachen.de
Stevens	Robert	rstevens@jhmi.edu
Stewart	William	william.stewart@glasgow.ac.uk
Steyerberg	Ewout W.	e.steyerberg@erasmusmc.nl
Stocchetti	Nino	stocchet@policlinico.mi.it
Sundström	Nina	Nina.Sundstrom@vll.se
Takala	Riikka	riikka.takala@tyks.fi
Tamás	Viktória	tamas.viktoria@pte.hu
Tamosuitis	Tomas	tomas.tamosuitis@kaunoklinikos.lt
Taylor	Mark Steven	marktrnava@gmail.com
Te Ao	Braden	braden.teao@aut.ac.nz
Tenovuo	Olli	olli.tenovuo@tyks.fi
Theadom	Alice	alice.theadom@aut.ac.nz
Thomas	Matt	Matt.Thomas@nbt.nhs.uk
Tibboel	Dick	d.tibboel@erasmusmc.nl
Timmers	Marjolijn	mtimmers@hotmail.com
Tolias	Christos	christos.tolias@nhs.net
Trapani	Tony	tony.trapani@monash.edu
Tudora	Cristina Maria	cristina.tudora@neuromed.ro
Unterberg	Andreas	Andreas.Unterberg@med.uni-heidelberg.de
Vajkoczy	Peter	Peter.Vajkoczy@charite.de
Valeinis	Egils	Egils.Valeinis@latnet.lv
Vallance	Shirley	S.Vallance@alfred.org.au
Vámos	Zoltán	azozoka@gmail.com
Van der Jagt	Mathieu	m.vanderjagt@erasmusmc.nl
van der Naalt	Joukje	j.van.der.naalt@umcg.nl
Van der Steen	Gregory	gregory@webstone.be
van Dijck	Jeroen T.J.M.	j.van.dijck@haaglandenmc.nl
van Essen	Thomas A.	T.A.van_Essen@lumc.nl

Van Hecke	Wim	wim.vanhecke@icomatrix.com
van Heugten	Caroline	Caroline.vanheugten@maastrichtuniversity.nl
Van Praag	Dominique	dominique.vanpraag@uza.be
Van Veen	Ernest	e.vanveen.1@erasmusmc.nl
van Wijk	Roel	roel-van-wijk@ziggo.nl
Vande Vyvere	Thijs	thijs.vandevyvere@icomatrix.com
Vargiolu	Alessia	neurorianimazione@hsgerardo.org
Vega	Emmanuel	emmanuel.vega@chru-lille.fr
Velt	Kimberley	k.velt@erasmusmc.nl
Verheyden	Jan	jan.verheyden@icomatrix.com
Vespa	Paul M.	PVespa@mednet.ucla.edu
Vik	Anne	anne.vik@ntnu.no
Vilcinis	Rimantas	rimantas.vilcinis@kaunoklinikos.lt
Volovici	Victor	v.volovici@erasmusmc.nl
von Steinbüchel	Nicole	nvsteinbuechel@med.uni-goettingen.de
Voormolen	Daphne	d.voormolen@erasmusmc.nl
Vulekovic	Petar	pvulekovic@gmail.com
Wang	Kevin K.W.	kawangwang17@gmail.com
Wiegers	Eveline	e.wiegers@erasmusmc.nl
Williams	Guy	gbw1000@wbic.cam.ac.uk
Wilson	Lindsay	l.wilson@stir.ac.uk
Winzeck	Stefan	sw742@cam.ac.uk
Wolf	Stefan	stefan.wolf@charite.de
Yang	Zhihui	zhihuiyang@ufl.edu
Ylén	Peter	peter.ylen@vtt.fi
Younsi	Alexander	alexander.younsi@med.uni-heidelberg.de
Zeiler	Frederick A.	umzeiler@myumanitoba.ca
Ziverte	Agate	agate.ziverte@inbox.lv
Zoerle	Tommaso	tommaso.zoerle@policlinico.mi.it

## 2. Additional methods

### Instrumental variable analysis

The main analysis associates centre-level treatment strategies to functional outcome to deduce effectiveness.

This natural experiment, in which patients are ‘allocated’ to one or another treatment strategy based on where the accident occurred, leads to considerable reduction of (unmeasured) confounding because patients are brought to hospitals without knowledge of neurosurgical treatment preference. This is an instrumental variable (IV) analysis, a quasi-experimental approach, where the IV centre ‘allocates’ patients to be exposed to different likelihoods of receiving acute surgical evacuation. IV analysis is less biased by (unmeasured) confounding by indication and is the preferred analytical method in observational studies on acute neurosurgical decisions in traumatic brain injury.<sup>1-3</sup> The validity depends on 1) the extent to which the instrument is associated with the intervention under study and 2) the absence of independent association with the outcome under study, so that the IV is not associated with the measured or unmeasured patient health status.

To test assumption 1, the association of the instrument with acute surgery was modelled. We calculated adjusted probabilities of surgery with a fixed-effects logistic regression model with the potential confounders age, GCS, pupil reactivity, hematoma size and midline shift as covariables. This model was extended with random intercepts for centre, and centre conditional on country to estimate centre effects on the probability of surgery.

To quantify this regional surgical variation, the median odds ratio (MOR) was calculated which is a measure of treatment variation between centres that is not explained by other factors in the model or attributable to chance.

The models with and without random-effects for centre were compared with the likelihood ratio test to determine the significance of the between-centre variation. Lastly, we added the neurosurgical treatment policy characteristics from the provider profiling to the model, to determine whether the variation attributable to centre is actually explained by neurosurgical policy characteristics. The fit of the models was compared using the Nagelkerke  $R^2$  as a measure for explained outcome variance.<sup>4</sup> Also, we included the partial F statistic as in our previous publication.<sup>3,5</sup>

Assumption 2 was evaluated by comparing the baseline prognosis, quantified by the CRASH-CT score, across the instrument. The CRASH-CT head injury model is a validated prognostic model based on the variables age, GCS, pupil reactivity to light, major extracranial injury, midline shift > 5mm, traumatic subarachnoid haemorrhage, and obliteration of the basal cisterns.<sup>6</sup> Additionally, we checked associations with measured confounders by calculating Spearman’s correlation coefficients between the IV and the prognostic scores of unfavourable outcomes. The IV was thereby checked according to recommendations.<sup>5</sup>



For the actual IV analyses, the centre coefficients from fixed-effects models, representing adjusted geographic treatment probabilities of acute surgery, were modelled in a random-effects ordinal regression with the aforementioned confounders as covariables. In this model, the random intercept represents the unexplained hospital effect (beyond all factors included in the model, including the instrument treatment preference) and should capture the measured and unmeasured hospital-level confounders, resulting in unbiased treatment effect estimates. To minimize the influence of chance, only hospitals that enrolled at least 15 patients (at least 10 patients in sensitivity analyses) were included in the IV analyses.

### **Sensitivity analyses**

The primary analysis was replicated 1) using a predefined IV for acute surgery from the provider profiling survey (dichotomized threshold for acute ASDH surgery policy: low vs high surgical threshold),<sup>7</sup> 2) without centres providing less than 10 patients, 3) with non-salvageable patients included,<sup>8</sup> 4) without patients with unreactive pupils (poor prognosis) and patients with GCS 15 (excellent prognosis) and 5) by restricting to patients meeting Brain Trauma Foundation (BTF)-guideline criteria for surgical evacuation, i.e. ASDH thickness greater than 10 mm and/or midline shift greater than 5 mm irrespective of the clinical condition. The first sensitivity analysis, using the predefined instrument from the provider profiling surveys, serves the goal to use another proxy for centre preference to function as an IV. In these provider profiling (before patient enrolment), centres reported whether their management protocol follows the BTF recommendation that every ASDH with a thickness > 10 mm or midline shift > 5 mm should be evacuated irrespective of clinical condition. The threshold for acute ASDH surgery was dichotomized accordingly: ‘Yes’, acute surgery following BTF guideline/low threshold for surgery; ‘No’, no management according to BTF guideline/high threshold for surgery). The predefined IV for acute surgery arises from this policy.

Additional analyses were performed with treatment defined at patient-level (exposed to intervention, yes/no), unadjusted, with multivariable regression and propensity score matching (PSM) and restricting to the BTF-guideline subgroup. The propensity of being exposed to the intervention was computed using multivariable logistic regression with acute surgery as the dependent variable. PSM was used to match exposed patients with non-exposed patients. The maximum difference between propensity scores was set at 0.10 (the caliper) using a nearest neighbour approach in 1:1 balance. For both the propensity score model and the covariable-adjusted

model, the aforementioned confounding variables of the primary analysis were considered independent variables. We used random-effects models with centre as the clustering variable for all patient-level analyses.

Subgroup analyses were performed for age (< 65 or  $\geq$  65 years), TBI severity (mild, moderate and severe TBI, corresponding to a Glasgow Coma Scale of 13-15, 9-12 and 3-8 respectively) and hematoma size (large vs small; 25 cm<sup>3</sup> cut-off) and presented in forest plots. No adjustments for multiple tests were made. The subgroup analyses were performed on centre-level, with IV analysis per subgroup, and on patient-level, with multivariable regression.

### **3. Additional results**

#### **Quantification of practice variation and instrumental variable assumptions**

Including the variable centre, in addition to patient characteristics, in a model predicting treatment increased the explained variance (Nagelkerke R<sup>2</sup>) from 54 to 63%. Furthermore, the acute surgical practice was partially explained by predefined neurosurgical treatment policies of the provider profiling. The reported policy of a low threshold for acute surgery was associated with (actual) acute surgery over and above most confounders (OR 2.14, 95% CI 1.09 – 4.11). For comparison, the variable ‘one nonreactive pupil’ was less strongly correlated with acute surgery (OR 1.90, 95% CI 1.01 – 3.60).

Also, the instrument was strongly associated with the intervention under study (partial F statistic 62). The correlation between instrument and prognosis was small (Supplemental Table 3). Thus, the testable assumptions for IV analyses were met.


#### **Sensitivity analyses**

On a continuous outcome scale in linear regression, higher adjusted surgical rates per centre were not associated with higher mean GOSE scores: for an increase from the 25th percentile to the 75th percentile of the range in exposure to the regional intervention preferences for acute surgery, the mean GOSE non-significantly decreased with 0.13 (95% CI: -0.36 – 0.09; Supplemental Figure 5).

Finally, to further test the consistency of the IV approach, we used other instrumental variables. The policy of a ‘low threshold for ASDH evacuation’, as reported in the prior performed provider profiling survey, was associated with similar GOSE as the ‘high threshold for surgery’ policy (common OR 1.05 [95% CI 0.85 – 1.32], Supplemental Table 4).

#### 4. Supplemental tables and figures

**Supplemental Figure 1. Sliding scale representation of clinical decision and inherent study population**



The scale depicts characteristics of clear-cut cases at either end of the clinical spectrum along which the treatment preference for acute surgery vs (initial) conservative treatment for ASDH differs. The right - red - end, represents patients with poor clinical characteristics for whom clinicians may not perform surgery or conservative treatment on ethical grounds but instead start comfort measures in a treatment-limiting setting. At the left – green – end, all patients will not be operated upon due to an anticipated good prognosis without need for acute evacuation. The window between the artificial divides of both ends, represents the resulting study population. The cut-offs of these divides cannot be reliably characterized because the window is applicable to those patients for whom the neurosurgeon may hypothetically be in clinical equipoise. Because an identical patient may be operated upon in one centre but not in another, it naturally follows that there is more than one valid treatment option. The varying centre policies thus lead to a group of patients for whom we infer clinical equipoise. Because centre policies are not measured per patient, it is not immediately clear what patient population the equipoise actually pertains to.

**Supplemental Table 1. Baseline and treatment characteristics of patients with traumatic acute subdural hematoma, comparing acute surgical evacuation and conservative treatment**

	ASDH treatment (n = 1318)				
	Acute surgery	Conservative treatment			
n	336	982	p value	SMD	Missing (%)
Age (median [IQR])	56 [40, 67]	58 [38, 72]	0.08	0.08	0.0
Sex (%)			0.06	0.12	0.0
Female	94 (28)	331 (34)			
Male	242 (72)	651 (66)			
White European	280 (83)	832 (85)	0.37	0.25	0.0
Years of education (median [IQR])	12 [10, 14]	12 [10, 15]	0.0301	0.20	42.1
Highest level of education			0.96	0.08	34.1
College or university	38 (19)	140 (20)			
Married or living with partner	174 (52)	485 (49)	0.13	0.21	0.4
Employment status before injury			0.10	0.27	17.2
Working (%)	127 (49)	358 (43)			
Pre-injury ASAPS (%)			0.0252	0.20	0.2
Healthy	159 (47)	469 (48)			
Mild systemic disease	106 (32)	370 (38)			
Severe systemic disease	49 (15)	111 (11)			
Threat to life	2 (1)	2 (0)			
Unknown	19 (6)	29 (3)			
History of cardiovascular disease	116 (35)	359 (37)	0.11	0.12	0.2
History of neurological disease	39 (12)	112 (11)	0.07	0.13	0.2
History of psychiatric disease	57 (17)	132 (13)	0.0062	0.19	0.4
History of oncological disease	20 (6)	58 (6)	0.0313	0.15	0.2
History of endocrine disease	41 (12)	164 (17)	0.0120	0.18	0.2
Injury area			0.0250	0.18	0.1
Urban (city)	278 (83)	749 (76)			
Rural	44 (13)	193 (20)			
Injury cause (%)			<0.0001	0.31	0.1
Road traffic incident	101 (30)	331 (34)			
Incidental fall	165 (49)	496 (51)			
Other non-intentional injury	11 (3)	41 (4)			
Violence	22 (7)	44 (4)			

Suicide attempt	6 (2)	9 (1)			
Unknown	26 (8)	24 (2)			
Other	5 (1)	36 (4)			
Injury mechanism			0.42	0.10	0.1
High velocity trauma (acceleration/deceleration)	80 (24)	255 (26)			
Direct impact: blow to head	32 (10)	95 (10)			
Direct impact: head against object	64 (20)	167 (17)			
Ground level fall	105 (31)	325 (33)			
Fall from height > 1 meter/5 stairs	88 (26)	234 (23)			
Alcohol consumption <sup>a</sup>			0.0002	0.27	6.7
No	114 (36)	456 (50)			
Yes	114 (36)	263 (29)			
Unknown	86 (27)	199 (22)			
Hypoxia (%) <sup>b</sup>			0.0049	0.21	0.8
No	267 (80)	854 (88)			
Definite	24 (7)	51 (5)			
Suspect	16 (5)	19 (2)			
Unknown	25 (8)	52 (5)			
Hypotension (%) <sup>c</sup>			0.0013	0.22	0.8
No	281 (85)	865 (89)			
Definite	15 (5)	52 (5)			
Suspect	14 (4)	10 (1)			
Unknown	22 (7)	49 (5)			
Any major extracranial injury (%) <sup>d</sup>	137 (41)	393 (40)	0.86	0.02	0.0
Face (%)	66 (20)	160 (16)	0.19	0.09	0.0
Thorax and chest (%)	76 (23)	225 (23)	0.97	0.01	0.0
Abdomen and pelvis (%)	33 (10)	109 (11)	0.58	0.04	0.0
Extremities (%)	23 (7)	124 (13)	0.0050	0.20	0.0
External (%)	9 (3)	16 (2)	0.32	0.07	0.0
Spine (%)	42 (12)	114 (12)	0.73	0.03	0.0
GCS (median [IQR])	7 [3, 11]	13 [8, 15]	<0.0001	0.86	4.3
GCS motor (median [IQR])	3 [1, 5]	6 [4, 6]	<0.0001	0.79	1.9
TBI severity (%)			<0.0001	0.82	4.3
Mild	67 (21)	537 (57)			

Moderate	56 (18)	141 (15)			
Severe	196 (61)	267 (28)			
Pupils (%)			<0.0001	0.62	4.8
Both reacting	215 (67)	847 (91)			
One reacting	44 (14)	31 (3)			
Both unreacting	62 (19)	53 (6)			
Any focal neurological deficit (%)			<0.01	0.55	0.2
No	157 (47)	713 (73)			
Yes	55 (16)	89 (9)			
Unknown	123 (37)	178 (18)			
Anti-coagulants or platelet aggregation inhibitors (%)			0.0335	0.19	0.2
No	235 (70)	734 (75)			
Anti-coagulants	33 (10)	75 (8)			
Platelet inhibitors	38 (11)	126 (13)			
Both	3 (1)	8 (1)			
Unknown	26 (8)	38 (4)			
Total volume of ASDH (cm <sup>3</sup> , median [IQR])	58 [28, 96]	9 [3, 23]	<0.0001	1.33	38
CT ASDH = large (%) <sup>e</sup>	252 (75)	100 (10)	<0.0001	1.2	0.1
CT SDH of mixed density (%)	22 (8)	43 (5)		0.1	12
CT midline shift (%) <sup>f</sup>	287 (85)	219 (22)		1.0	0.1
CT DAI (%)			0.81	0.04	0.1
No	268 (80)	797 (81)			
Yes	43 (13)	123 (13)			
Unknown	24 (7)	61 (6)			
CT depressed skull fracture (%)			0.0203	0.17	0.1
No	260 (78)	825 (84)			
Closed	62 (19)	123 (13)			
Open	13 (4)	33 (3)			
CT contusion (%)			<0.0001	0.34	0.2
No	134 (40)	375 (38)			
Small	132 (39)	506 (52)			
Large	60 (18)	95 (10)			
Unknown	9 (3)	5 (1)			
CT SAH (%)			0.0312	0.18	0.1
No	117 (35)	329 (34)			

Basal	26 (8)	76 (8)			
Cortical	135 (40)	462 (47)			
Basal and Cortical	58 (17)	114 (12)			
CT basal cisterns absent/compressed (%)	156 (47)	97 (10)	<0.0001	0.90	0.3
Treatment characteristics during primary admission					
Surgery type		Na			
DC	91 (27)				
Craniotomy	245 (73)				
Time injury to surgery (min, median [IQR])	230 [152, 391]				4.8
Secondary or delayed surgery (%)	93 (28)	107 (11)			
DC	51 (55)	52 (49)			
ASDH	32 (34)	41 (38)			
Contusion/ICH	10 (11)	14 (13)			
Time injury to secondary or delayed surgery (min, median [IQR])	1115 [360, 6057]	1149 [486, 5077]			23
Other surgery (during admission, after primary surgery or initial conservative treatment, %)					
Chronic subdural hematoma	1 (0)	8 (1)			
Epidural hematoma	11 (3)	8 (1)			
Cranioplasty	22 (7)	2 (0)			
Extracranial surgery (%)	69 (21)	200 (20)	1.0	<0.01	0.0
ICP monitor (%)	236 (70)	313 (32)	<0.0001	0.83	0.0
ICP device (%)			0.37	0.12	0.0
Ventricular	33 (14)	47 (15)			
Parenchymal	184 (79)	252 (81)			
Other	17 (7)	14 (4)			
ICP (median [IQR])	12 [8, 15]	12 [9, 15]	0.37	0.07	
CPP (median [IQR])	73 [67, 77]	74 [68, 80]	0.10	0.19	
TIL (median [IQR])	5 [2, 9]	2 [0, 6]	<0.0001	0.49	
Discharge destination (%)					
Other hospital	63 (30)	158 (21)	0.0120	0.81	10



Rehabilitation unit	84 (41)	162 (22)			
Nursing home	16 (8)	28 (4)			
Home	35 (17)	389 (52)			
Unknown	0 (0)	1 (0)			
Other	9 (4)	12 (2)			
Treatment during follow-up (after discharge)					
Hydrocephalus	9 (3)	5 (1)			
Chronic subdural hematoma	2 (1)	12 (1)			
Cranioplasty	25 (7)	17 (2)			

Abbreviations: AIS, Abbreviated Injury Scale; ASAPS, American Society of Anesthesiologists classification system; ASDH, acute subdural hematoma; CPP, cerebral perfusion pressure; DAI, diffuse axonal injury; DC, decompressive craniectomy; GCS, Glasgow Coma Scale; ICP, intracranial pressure; IQR, interquartile range; Na, not applicable; SAH, subarachnoid hemorrhage; SMD, standardized mean difference; TIL, Therapy Intensity Level.

<sup>a</sup> On presentation the behavioral history of the patient was recorded. This variable reflects his/her use in the past three months of alcoholic beverages (beer, wine, spirits) (>2/day).

<sup>b</sup> Second insult during the pre-hospital or ER phase, defined as PaO<sub>2</sub> < 8 kPa (60 mmHg)/SaO<sub>2</sub> < 90%. 'Suspected' was scored if the patient did not have documented hypoxia by PaO<sub>2</sub> or SaO<sub>2</sub>, but there was a clinical suspicion, as evidenced by for example cyanosis, apnoea or respiratory distress.

<sup>c</sup> Second insult during the pre-hospital or ER phase, defined as systolic BP < 90 mmHg. 'Suspected' was scored if the patient did not have a documented blood pressure, but was reported to be in shock or have an absent brachial pulse (not related to injury of the extremity).

<sup>d</sup> AIS ≥ 3.

<sup>e</sup> Large is defined as larger than 25 cm<sup>3</sup>.

<sup>f</sup> Midline shift present is classified as being more than 5 mm.

**Supplemental Table 2. Baseline and hospital characteristics of non-salvageable patients**

<b>Patient characteristic</b>	
n	89
Age (median [IQR])	74 [57, 79]
Sex = male (%)	61 (69)
ASAPS (%)	
Healthy	23 (26)
Mild systemic disease	39 (44)
Severe systemic disease	16 (18)
Threat to life	1 (1)
Unknown	9 (10)
Injury cause (%)	
Road traffic incident	26 (29)
Incidental fall	55 (62)
Other non-intentional injury	1 (1)
Violence	1 (1)
Suicide attempt	2 (2)
Unknown	3 (3)
Other	1 (1)
Hypoxia (%) <sup>a</sup>	
No	66 (75)
Definite	15 (17)
Suspect	3 (3)
Unknown	4 (5)
Hypotension (%) <sup>b</sup>	
No	63 (72)
Definite	17 (19)
Suspect	3 (3)
Unknown	5 (6)
Any major extracranial injury (%) <sup>c</sup>	34 (38)
GCS (median [IQR])	3 [3, 5]
GCS motor (median [IQR])	1 [1, 2]
TBI severity (%)	
Mild	2 (2)
Moderate	8 (10)
Severe	73 (88)

Pupils (%)	
Both reacting	21 (24)
One reacting	7 (8)
Both unreacting	59 (68)
Any focal neurological deficit (%)	
No	38 (43)
Yes	11 (12)
Unknown	40 (45)
Anti-coagulants or platelet aggregation inhibitors (%)	
No	46 (52)
Anti-coagulants	20 (23)
Platelet inhibitors	13 (15)
Both	2 (2)
Unknown	7 (8)
Total volume of ASDH (cm <sup>3</sup> , median [IQR])	67 [18, 111]
CT ASDH = large (%) <sup>d</sup>	68 (76)
CT SDH of mixed density (%)	10 (12)
CT midline shift = yes (%) <sup>e</sup>	63 (71)
CT DAI (%)	
No	71 (80)
Yes	9 (10)
Unknown	9 (10)
CT depressed skull fracture (%)	
No	62 (70)
Closed	23 (26)
Open	4 (4)
CT contusion (%)	
No	34 (39)
Small	22 (25)
Large	29 (33)
Unknown	3 (3)
CT SAH (%)	
No	21 (24)
Basal	9 (10)


Cortical	31 (35)
Basal and Cortical	28 (31)
CT basal cisterns absent/compressed = yes (%)	55 (62)
In-hospital mortality (%)	85 (96)
Time admission to death (hours, median [IQR])	21 [6, 50]
Decision to withdraw active treatment (%)	67 (79)
Multidisciplinary	50 (75)
By a single physician	11 (16)
With relatives	6 (9)
Withdrawal of life-sustaining measures <sup>a</sup>	
For severity of TBI	45 (51)
For reason of age	9 (10)
For reason of co-morbidities	3 (4)
On request of relatives	6 (7)
Following living will of patient	5 (6)
Time injury to decision of withdrawal of care (hours, median [IQR])	6 [3, 27]
Discharge destination (%)	
Home	1 (1)
Nursing home	2 (2)
Other hospital	1 (1)
GOSE 6-months (%)	
1=Dead	88 (99)
2=Vegetative state/3=Lower severe disability	0
4=Upper severe disability	0
5=Lower moderate disability	0
6=Upper moderate disability	0
7=Lower good recovery	0
8=Upper good recovery	0

Abbreviations: GOS(E), Glasgow Outcome Scale Extended; IQR, interquartile range; TBI, traumatic brain injury.


<sup>a</sup> Mechanical ventilation; vaso-active medication; continuous veno-venous hemofiltration; intravenous fluids.

**Supplemental Figure 2. Motivations for acute surgery, conservative treatment, and secondary surgery after initial conservative treatment**


**A**



**B**




**C**



The graphs show the reasons for acute surgery (A), conservative treatment (B), and secondary surgery after initial conservative treatment (C), visually represented as proportions of the total (sub)group, as judged by the treating physician based on the first CT-scan (A,B and C) or a follow-up CT-scan (D). Definitions for clinical deterioration: a spontaneous decrease in the Glasgow Coma Scale motor score  $\geq 2$  points (compared with the previous examination), a new loss of pupillary reactivity, development of pupillary asymmetry  $\geq 2$  mm or any other deterioration in neurological status.

Supplemental Figure 3. Proportions per centre with acute surgery of all ASDH patients





**Supplemental Table 3. Baseline characteristics of the cohort for the post-hoc analysis, across centres with different preferences for immediate treatment of acute subdural hematoma**

	Treatment preference (observed acute surgery rates) <sup>a</sup>				p value	SMD
	1 (<14%)	2 (14 – 24%)	3 (24 – 36%)	4 (> 35%)		
n	140	134	152	125		
Age (median [IQR])	55 [40, 67]	50 [32, 65]	56 [38, 68]	63 [42, 71]	0.0332	0.18
Sex					0.96	0.02
Female	35 (25)	45 (32)	59 (39)	30 (24)		
Male	105 (75)	89 (66)	93 (61)	95 (76)		
White European	123 (88)	111 (83)	133 (88)	109 (87)	0.74	0.36
Years of education (median [IQR])	13 [11, 16]	12 [8, 14]	12 [10, 14]	12 [9, 14]	0.0225	0.31
College or university education	35 (25)	29 (22)	22 (14)	18 (14)	0.06	0.35
Married or living with partner	72 (51)	72 (54)	84 (55)	72 (57)	0.21	0.28
Working before injury (%)	62 (44)	51 (38)	56 (36)	47 (8)	0.18	0.40
ASAPS (%)					0.81	0.12
Healthy	57 (41)	88 (66)	85 (56)	50 (40)		
Mild systemic disease	64 (46)	32 (24)	45 (30)	53 (42)		
Severe systemic disease	13 (9)	14 (10)	18 (12)	14 (11)		
Threat to life	0 (0)	0 (0)	2 (1)	0 (0)		
Unknown	6 (4)	0 (0)	2 (1)	8 (6)		
History of cardiovascular disease	42 (30)	33 (25)	53 (35)	53 (42)	0.07	0.28
Alcohol consumption <sup>b</sup>	32 (23)	49 (37)	55 (36)	19 (15)	0.0340	0.32
Injury mechanism and cause					0.11	0.40
High velocity trauma	46 (33)	44 (33)	40 (26)	33 (26)		
Incidental ground level fall	73 (52)	71 (53)	84 (55)	65 (52)		
Highest trained bystander (%)					0.38	0.32
None	6 (4)	10 (7)	11 (7)	9 (7)		
Untrained person (bystander)	2 (1)	2 (1)	3 (2)	2 (2)		
Paramedic	41 (29)	34 (25)	28 (18)	24 (19)		
Nurse	25 (18)	23 (17)	36 (24)	19 (15)		
Physician	38 (27)	26 (19)	44 (29)	40 (32)		
Medical rescue team	27 (19)	38 (28)	28 (18)	31 (25)		
Secondary referral (%)	37 (26)	40 (30)	42 (28)	27 (22)	0.44	0.11
Arrival Method (%)					0.27	0.28
Ambulance	111 (79)	97 (72)	112 (74)	88 (70)		
Helicopter	14 (10)	15 (11)	18 (12)	18 (14)		
Medical mobile team	8 (6)	8 (6)	7 (5)	9 (7)		
CPR (%)	5 (4)	9 (7)	6 (4)	1 (1)	0.27	0.19

IV Fluids (%)	50 (36)	47 (35)	58 (38)	52 (42)	0.39	0.12
Intubation (%)	38 (27)	34 (25)	47 (31)	41 (33)	0.52	0.14
Supplemental oxygen (%)	60 (43)	64 (48)	67 (44)	62 (50)	0.11	0.26
Ventilation (%)	35 (25)	33 (25)	39 (26)	40 (32)	0.29	0.19
Hypoxia (%) <sup>c</sup>					0.71	0.15
No	121 (86)	111 (83)	138 (91)	111 (89)		
Definite	5 (4)	8 (6)	10 (7)	6 (5)		
Suspect	6 (4)	3 (2)	2 (1)	3 (2)		
Hypotension (%) <sup>d</sup>					0.66	0.16
No	123 (88)	107 (80)	143 (94)	104 (83)		
Definite	7 (5)	8 (6)	4 (3)	10 (8)		
Suspect	1 (1)	4 (3)	2 (1)	2 (2)		
Any major extracranial injury (%) <sup>e</sup>	50 (36)	63 (47)	63 (41)	60 (48)	0.07	0.25
GCS baseline (median [IQR])	10 [5, 13]	9 [5, 13]	9 [6, 13]	10 [7, 13]	0.28	0.14
GCS motor baseline (median [IQR])	5 [2, 6]	5 [2, 6]	5 [1, 6]	5 [4, 6]	0.37	0.14
Any focal neurological deficit (%)					0.0022	0.44
No	78 (56)	82 (61)	92 (61)	92 (74)		
Yes	15 (11)	23 (17)	27 (18)	14 (11)		
Unknown	47 (34)	29 (22)	33 (22)	19 (15)		
Anti-coagulants or platelet aggregation inhibitors (%)					0.21	0.30
No	105 (75)	111 (83)	121 (80)	80 (64)		
Anti-coagulants	8 (6)	7 (5)	11 (7)	8 (6)		
Platelet inhibitors	15 (11)	15 (11)	16 (11)	22 (18)		
Both	0 (0)	0 (0)	2 (1)	2 (2)		
Unknown	12 (9)	1 (1)	2 (1)	13 (10)		
Total volume of ASDH (cm <sup>3</sup> , median [IQR])	14 [4, 29]	10 [4, 28]	23 [6, 58]	20 [6, 48]	0.10	0.25
CT ASDH = large (%) <sup>f</sup>	31 (22)	36 (27)	57 (38)	36 (29)	0.27	0.15
CT midline shift (%) <sup>g</sup>	74 (53)	55 (41)	68 (45)	43 (34)	0.0038	0.38
CT contusion (%)					0.0021	0.44
No	27 (19)	53 (40)	44 (29)	46 (37)		
Small	91 (65)	64 (48)	79 (52)	70 (56)		
Large	22 (16)	16 (12)	27 (18)	9 (7)		
Unknown	0 (0)	1 (1)	2 (1)	0 (0)		
CT subarachnoid haemorrhage (%)					0.32	0.23
No	31 (22)	27 (20)	43 (28)	38 (30)		
Basal	9 (6)	15 (11)	18 (12)	11 (9)		
Cortical	75 (54)	75 (56)	76 (50)	55 (44)		
Basal and Cortical	25 (18)	17 (13)	15 (10)	21 (17)		

CT basal cisterns absent/compressed (%)	30 (21)	30 (22)	37 (24)	21 (17)	0.42	0.12
Mean predicted 6-month unfavourable outcome (GOS $\leq$ 3, %, median [IQR]) <sup>h</sup>	57 [39, 74]	52 [29, 73]	60 [31, 78]	63 [34, 76]	0.90	0.05
Centre characteristics						
Academic hospital (vs. non-academic)	140 (100)	134 (100)	130 (86)	125 (100)	NA	<0.0001
Number of beds (%)	915 [632, 1158]	1200 [882, 1300]	924 [870, 1212]	850 [665, 1213]	1.00	0.11
Residency program neurosurgery	140 (100)	134 (100)	152 (100)	125 (100)	NA	<0.0001
Trauma centre designation					<0.01	0.48
- Level I	140 (70)	92 (69)	121 (100)	106 (100)		
- Level II	0 (0)	15 (11)	0 (0)	0 (0)		
- Level III	0 (0)	27 (20)	0 (0)	0 (0)		
Urban location (vs. suburban and rural location)	134 (100)	152 (100)	125 (100)	134 (100)	NA	<0.0001
Neurosurgeon staffing (FTE)	14 [14, 16]	12 [11, 12]	10 [8, 14]	8 [7, 11]	0.03	2.02
Number of surgeries for ASDH in 2013	92 [68, 101]	18 [13, 24]	25 [24, 28]	21 [10, 30]	0.14	1.18
Low threshold policy for acute surgery in ASDH <sup>i</sup>	44 (31)	20 (15)	103 (68)	64 (51)	0.0017	0.41

Abbreviations: AIS, Abbreviated Injury Scale; ASAPS, American Society of Anesthesiologists classification system; ASDH, acute subdural hematoma; FTE, full time equivalent; GCS, Glasgow Coma Scale; GOS(E), Glasgow Outcome Scale Extended; IQR, interquartile range.

<sup>a</sup> Treatment preference as defined by the case-mix adjusted probability of undergoing acute surgery (as opposed to initial conservative treatment) based on the observed acute surgery rates per centre. The first category is less aggressive than the second and the second is less aggressive than the third and so forth. Importantly, the IV analysis used the acute surgery rates as continuous preference, the quartiles are presented for purposes of interpretability of baseline comparability.

<sup>b</sup> On presentation the behavioural history of the patient was recorded. This variable reflects the past three months consumption of alcoholic beverages (beer, wine, spirits) (>2/day).

<sup>c</sup> Second insult during the pre-hospital or ER phase, defined as PaO<sub>2</sub> < 8 kPa (60 mmHg)/SaO<sub>2</sub> < 90%. "Suspected" was scored if the patient did not have documented hypoxia by PaO<sub>2</sub> or SaO<sub>2</sub>, but there was a clinical suspicion, as evidenced by for example cyanosis, apnoea or respiratory distress.

<sup>d</sup> Second insult during the pre-hospital or ER phase, defined as systolic BP < 90 mmHg. "Suspected" was scored if the patient did not have a documented blood pressure, but was reported to be in shock or have an absent brachial pulse (not related to injury of the extremity).

<sup>e</sup> AIS  $\geq$  3.

<sup>f</sup> Large is defined as larger than 25 cm<sup>3</sup>.

<sup>g</sup> Midline shift present is classified as being more than 5 mm.

<sup>h</sup> TBI severity as summarized in predicted unfavourable outcome, proportion with a Glasgow Outcome Scale  $\leq 3$ , based on CRASH-CT variables.

<sup>i</sup> Before patient inclusion in CENTER-TBI, treatment policies per centre were captured by provider profile surveys, including the policy towards acute surgery. The resulting threshold for acute ASDH surgery is dichotomized based on this distinction: 'Low', low threshold for surgery; 'High', high threshold for surgery).


**Supplemental Table 4. Assumptions for instrumental variable analysis**

<b>IV assumptions</b>	<b>Acute surgery</b>
Assumption 1: instrument association with intervention	
Partial F statistic	61.8
Assumption 2: instrument association with prognosis	
Spearman's Rho correlation with $P_{\text{unfavourable}}^a$	0.02

Abbreviation: IV, instrumental variable

<sup>a</sup> Prognosis as summarized in CT-CRASH score, predicted unfavourable outcome (proportion with a Glasgow Outcome Scale  $\leq$  3)

Supplemental Figure 4. Functional outcome with centres with different rates of acute surgery



Graphical illustration to estimate the incremental effect of treatment preference (more acute surgery) on 6-months GOSE. Each circle represents a centre with area proportional to the number of patients. The fitted line is the result of a random-effects linear model with dotted lines reporting the 95% confidence interval with a Beta of -0.13 (95% CI: -0.36 – 0.09) for acute surgery, adjusted for confounders.

**Supplemental Table 5. Primary and secondary outcomes and association with acute surgery of the post-hoc analysis**


	Treatment preference (observed acute surgery rates)				Effect variable	Adjusted value (95% CI) <sup>a</sup>
	1 (<14%)	2 (14 – 24%)	3 (24 – 36%)	4 (> 35%)		
Primary outcome: GOSE at 6 months (median [IQR])	5 [3 to 7]	5 [3 to 7]	5 [3 to 6]	4 [3 to 7]	Common odds ratio	0.91 (0.72 – 1.18)
Secondary outcomes						
In-hospital mortality	26 (19)	24 (18)	24 (16)	28 (22)	Odds ratio	0.99 (0.63 – 1.38)
GOSE of 7 or 8 (%)	38 (27)	42 (32)	36 (23)	33 (26)	Odds ratio	0.87 (0.62 – 1.17)
GOSE of 5-8 (%)	79 (57)	88 (66)	79 (51)	55 (43)	Odds ratio	0.83 (0.65 – 1.14)
GOSE of 4-8 (%)	94 (68)	95 (71)	94 (61)	67 (53)	Odds ratio	0.81 (0.62 – 1.08)
Qolibri (median [IQR]) at 6 months <sup>b</sup>	67 [54 to 89]	74 [62 to 87]	66 [51 to 86]	76 [62 to 85]	Beta	0.49 (-4.06 – 5.04)

Abbreviations: CI, confidence interval; GOSE, Glasgow Outcome Scale Extended; IQR, interquartile range; Qolibri, Quality of Life after Brain Injury Scale;

<sup>a</sup> Estimates from random-effects multivariable logistic regression with the instrument, adjusted probability of performing acute surgery as treatment variable. Confounding was furthermore addressed by adjusting for the a-priori defined variables age, GCS, focal neurological deficit, hematoma size and midline shift. The (common) odds ratio are presented as comparisons between the first quartile and the fourth quartile (IQR) of the instrument (the adjusted probabilities for undergoing acute surgery).

<sup>b</sup> Qolibri is a standardized health specific quality of life measure specifically designed for and validated for outcome assessment in patients with brain injury. It is a numerical scale with scores ranging from 0 to 100 with higher scores indicating a better quality of life. The score was available for 59 patients of the acute surgery group, 225 patients of the conservative management group.

**Supplemental Figure 5. Subgroup analyses for acute surgery in the instrumental variable cohort.**



The panel shows the common odds ratio for improvement on the ordinal Glasgow Outcome Scale Extended for acute surgery, stratified for subgroups, using ordinal logistic regressions with random-effects and adjustments for confounders (see 'Methods/Statistical Analysis').

The variation in acute surgery is presented as the range for centres providing at least 15 patients. Exploratory subgroup analyses were displayed as forest plots using the primary outcome as dependent variable without the subgroup-defining variable on categorized regression models. The moderate TBI subgroup only had 1 centre and, hence, no estimate could be calculated.



**Supplemental Table 6. Results of sensitivity analyses: comparing analytical methods to adjust for confounding by indication**

<b>Approach</b>	<b>Acute surgery (OR 95 % CI, number of patients)</b>
Unadjusted model	0.32 (0.26 - 0.40, n = 1318)
Covariable adjustment in multivariable regression <sup>a</sup>	0.85 (0.60 - 1.19, n = 1318)
Patients with both reactive pupils and GCS < 15	0.87 (0.55 - 1.39, n = 665)
Restriction (to patients meeting BTF guidelines) <sup>b</sup>	0.65 (0.48 - 1.28, n = 414)
Propensity score matching <sup>c</sup>	0.89 (0.57 - 1.36, n = 332)
Patients with both reactive pupils and GCS < 15	0.87 (0.44 - 1.57, n = 184)
Instrumental variable <sup>d</sup>	
Patients with both reactive pupils and GCS < 15 <sup>e</sup>	0.91 (0.72 - 1.18, n = 665)
Predefined instrument (of provider profiling) <sup>f</sup>	1.05 (0.85 - 1.32, n = 1318)
With the cohort with centres < 10 patients excluded	0.87 (0.66 - 1.0, n = 1227)
On BTF subgroup <sup>g</sup>	0.82 (0.47 - 1.50, n = 414)
With the cohort including the non-salvageable patients (excluded in primary analysis)	1.01 (0.87 - 1.27, n = 1407)

Abbreviations: BTF, Brain Trauma Foundation; CI, confidence interval; GCS, Glasgow Coma Scale; OR, odds ratio.

All ORs represent the effect on the Glasgow Outcome Scale Extended estimated with proportional odds regression models

<sup>a</sup> Model was adjusted for the following confounders: age, GCS, pupillary reactivity, midline shift, hematoma size.

<sup>b</sup> This analysis is performed restricting to patients meeting the BTF guidelines for surgical evacuation, i.e. when ASDH thickness is greater than 10 mm and/or with midline shift greater than 5 mm irrespective of the clinical condition, in the covariable adjusted model.

<sup>c</sup> A propensity score was calculated based on the following variables: age, GCS, pupillary reaction, midline shift, hematoma size and concomitant contusion, including random-effects term for centre.

<sup>d</sup> In these instrumental variable analyses, the adjusted common OR indicates the odds of a more favourable outcome for an increase from the 25th percentile to the 75th percentile of the range in exposure to the regional intervention preferences for acute surgery, adjusted for age, GCS, pupillary reactivity, midline shift, hematoma size and random hospital effect.

<sup>e</sup> This analysis is performed without patients with one or both unreactive pupil(s) (poor prognosis) and patients with GCS 15 (excellent prognosis).

<sup>f</sup> Centres provided - before patient enrolment - whether their management protocol follows the Brain Trauma Foundation (BTF) recommendation: surgical evacuation in case of a hematoma > 10mm or midline shift > 5 mm, irrespective of clinical condition. The threshold for acute ASDH surgery was dichotomized accordingly: 'Yes', acute surgery following BTF guideline/ low threshold for surgery; 'No', no management according to BTF guideline/high threshold for surgery).

<sup>g</sup> This analysis is performed restricting to patients meeting the BTF guidelines for surgical evacuation, i.e. when ASDH thickness is greater than 10 mm and/or with midline shift greater than 5 mm irrespective of the clinical condition.

**Supplemental Table 7: Baseline characteristics of propensity matched cohort, comparing acute surgical evacuation with conservative treatment**

Patient characteristic	Treatment status (n = 332)		SMD
	Acute surgery	Conservative treatment	
n	166	166	
Age (median [IQR])	56 [36, 66]	57 [32, 72]	0.1
ASAPS (%)			0.2
Healthy	76 (46)	73 (44)	
Mild systemic disease	64 (39)	61 (37)	
Severe systemic disease	17 (10)	23 (14)	
Threat to life	0 (0)	1 (1)	
Unknown	9 (5)	8 (5)	
Hypoxia (%) <sup>a</sup>			0.2
No	140 (84)	132 (80)	
Definite	10 (6)	16 (10)	
Suspect	5 (3)	4 (2)	
Unknown	11 (7)	14 (8)	
Hypotension (%) <sup>b</sup>			0.3
No	140 (84)	142 (86)	
Definite	7 (4)	11 (7)	
Suspect	9 (5)	1 (1)	
Unknown	10 (6)	12 (7)	
Any major extracranial injury (%) <sup>c</sup>	62 (37)	68 (41)	0.1
GCS (median [IQR])	9 [4, 13]	10 [5, 14]	0.1
GCS motor (median [IQR])	5 [1, 6]	5 [1, 6]	0.2
Pupils (%)			0.1
Both reacting	126 (76)	131 (79)	
One reacting	17 (10)	14 (8)	
Both unreacting	23 (14)	21 (13)	
Any focal neurological deficit (%)			0.2
No	88 (53)	99 (60)	
Yes	25 (15)	17 (10)	
Unknown	53 (32)	50 (30)	
Anti-coagulants or platelet aggregation inhibitors (%)			0.2

No	116 (70)	114 (69)	
Anti-coagulants	14 (8)	17 (10)	
Platelet inhibitors	21 (13)	21 (13)	
Both	1 (1)	4 (2)	
Unknown	14 (8)	10 (6)	
CT ASDH = large (%) <sup>d</sup>	85 (51)	84 (51)	0-0
CT midline shift (%) <sup>e</sup>	5 [0, 10]	3 [0, 6]	0-4
CT contusion (%)			0-2
No	63 (38)	67 (40)	
Small	65 (39)	66 (40)	
Large	31 (19)	31 (19)	
Unknown	7 (4)	2 (1)	
GOSE 6-months (%)			0-3
1=Dead	43 (26)	55 (33)	
2=Vegetative state/3=Lower severe disability	38 (23)	24 (15)	
4=Upper severe disability	15 (9)	8 (5)	
5=Lower moderate disability	24 (15)	23 (14)	
6=Upper moderate disability	9 (5)	12 (7)	
7=Lower good recovery	21 (13)	19 (11)	
8=Upper good recovery	16 (10)	25 (15)	

Abbreviations: ASAPS, American Society of Anesthesiologists classification system; ASDH, acute subdural hematoma; GCS, Glasgow Coma Scale; GOS(E), Glasgow Outcome Scale Extended; IQR, interquartile range; SMD, standardized mean difference.

<sup>a</sup> Second insult during the pre-hospital or ER phase, defined as PaO<sub>2</sub> < 8 kPa (60 mmHg)/SaO<sub>2</sub> < 90%. 'Suspected' was scored if the patient did not have documented hypoxia by PaO<sub>2</sub> or SaO<sub>2</sub>, but there was a clinical suspicion, as evidenced by for example cyanosis, apnoea or respiratory distress.


<sup>b</sup> Second insult during the pre-hospital or ER phase, defined as systolic BP < 90 mmHg. 'Suspected' was scored if the patient did not have a documented blood pressure, but was reported to be in shock or have an absent brachial pulse (not related to injury of the extremity).

<sup>c</sup> AIS ≥ 3.

<sup>d</sup> Large is defined as larger than 25 cm<sup>3</sup>.

<sup>e</sup> Midline shift present is classified as being more than 5 mm.

**Supplemental Figure 6. Propensity scores distribution of nonmatched cohorts and propensity matched cohorts for acute surgery**



The figure depicts the distribution of propensity scores between matched and unmatched patients treatment- (surgical hematoma evacuation) and control-units (conservative treatment)

**Supplemental Table 8. Hospital course and outcomes**

Outcome	Treatment preference (observed acute surgery rates)			
	1 (<13%)	2 (13 – 24%)	3 (24 – 35%)	4 (> 35%)
n	229	348	291	292
Any neuroworsening = yes (%) <sup>a</sup>	51 (22)	113 (32)	118 (41)	91 (31)
Progression on CT = present (%) <sup>b</sup>	42 (18)	94 (27)	91 (31)	81 (28)
Length of hospital stay (days, [IQR])	10 [5, 21]	12 [5, 28]	14 [5, 28]	16 [9, 29]
Decision to withdraw active treatment (%)	15 (7)	30 (9)	41 (13)	26 (9)
Discharge destination (%)				
Other hospital	51 (22)	87 (25)	62 (21)	35 (12)
Rehabilitation unit	18 (8)	76 (22)	59 (20)	85 (29)
Nursing home	14 (6)	9 (3)	25 (9)	16 (5)
Home	94 (41)	130 (37)	88 (30)	94 (32)
Unknown	12 (5)	11 (3)	13 (4)	11 (4)
Other	40 (17)	35 (10)	44 (15)	51 (17)
GOSE 6-months (%)				
1=Dead	45 (20)	51 (15)	65 (22)	69 (24)
2=Vegetative state/3=Lower severe disability	31 (14)	48 (14)	43 (15)	58 (20)
4=Upper severe disability	22 (10)	18 (5)	25 (9)	12 (4)
5=Lower moderate disability	21 (9)	53 (15)	35 (12)	32 (11)
6=Upper moderate disability	18 (8)	50 (14)	35 (12)	25 (9)
7=Lower good recovery	30 (13)	58 (17)	48 (16)	30 (10)
8=Upper good recovery	62 (27)	70 (20)	40 (14)	66 (23)

<sup>a</sup> Neuroworsening is defined as: a spontaneous decrease in the Glasgow Coma Scale motor score  $\geq 2$  points (compared with the previous examination), a new loss of pupillary reactivity, development of pupillary asymmetry  $\geq 2$  mm, and/or deterioration in neurological or CT status sufficient to warrant immediate medical or surgical intervention.

<sup>b</sup> Progression on the CT scan during the hospital course is defined as an increase in initial lesion and/or the development of a new lesion.

## 5. Search string strategy and output

Total d.d. 24-11-2021: 2422 references, sourced from PubMed, Embase (OVID-version), Web of Science, Cochrane Library, CENTRAL, CINAHL (EbscoHOST), Emcare (OVID-version), Academic Search, ScienceDirect, Google Scholar.

P: [Acute subdural haematoma, hematoma, haemorrhage, hemorrhage](#)

I: [Surgery/\(neuro-\)surgical intervention, evacuation/craniotomy/\(decompressive\) \(hemi-\)craniectomy](#)

C: [Expectant approach/medical treatment/steroids/mannitol/observation/non-surgical treatment](#)

O: [Survival/Glasgow Outcome Scale/Rankin score](#)

Databases:

### PubMed

```
((("Hematoma, Subdural"[majr:noexp] OR "Hematoma, Subdural, Acute"[majr] OR "subdural hematoma"[ti] OR "subdural hematomas"[ti] OR "subdural haematoma"[ti] OR "subdural haematomas"[ti] OR "sub dural hematoma"[ti] OR "traumatic subdural hematoma"[ti] OR "post-traumatic subdural hematoma"[ti] OR "subdural bleeding"[ti] OR "subdural haemorrhage"[ti] OR "subdural hemorrhage"[ti]) AND ("surgery"[Subheading] OR "surgery"[tiab] OR "surgical procedures, operative"[mesh] OR "surgical"[tiab] OR neurosurgical[tiab] OR "neurosurgical procedures"[mesh] OR "neurosurgery"[tiab] OR "neurosurgery"[mesh] OR evacuation[tiab] OR "craniotomy"[mesh] OR "craniotomy"[tiab] OR craniotom*[tiab] OR decompressive[tiab] OR "decompression"[mesh] OR "decompression"[tiab] OR hemicraniectomy[tiab] OR hemicraniectom*[tiab] OR haemicraniecto*[tiab] OR craniectomy[tiab] OR craniectom*[tiab]) AND (expectant[tiab] OR "medical treatment"[tiab] OR "medical therapy"[tiab] OR "drug therapy"[Subheading] OR "drug therapy"[tiab] OR "drug therapy"[mesh] OR "steroids"[mesh] OR "mannitol"[mesh] OR "mannitol"[tiab] OR "observation"[mesh] OR "observation"[tiab] OR "non-surgical"[tiab] OR "non-operative"[tiab] OR conservative[tiab] OR conservativ*[tiab] OR "wait and see"[tiab] OR "Unconsciousness"[mesh])) OR (("Hematoma, Subdural"[majr:noexp] OR "Hematoma, Subdural, Acute"[mesh] OR "subdural hematoma"[tiab] OR "subdural hematomas"[tiab] OR "subdural haematoma"[tiab] OR "subdural haematomas"[tiab] OR "sub dural hematoma"[tiab] OR "traumatic subdural hematoma"[tiab] OR "post-traumatic subdural hematoma"[tiab] OR "subdural bleeding"[tiab] OR "subdural haemorrhage"[tiab] OR "subdural hemorrhage"[tiab]) AND ("surgery"[Subheading] OR "surgery"[tiab] OR "surgical procedures, operative"[mesh] OR "surgical"[tiab] OR surgical*[tiab] OR neurosurgical[tiab] OR "neurosurgical procedures"[mesh] OR "neurosurgery"[tiab] OR "neurosurgery"[mesh] OR evacuation[tiab] OR "craniotomy"[mesh] OR "craniotomy"[tiab] OR craniotom*[tiab] OR decompressive[tiab] OR "decompression"[mesh] OR "decompression"[tiab] OR hemicraniectomy[tiab] OR hemicraniectom*[tiab] OR haemicraniecto*[tiab] OR craniectomy[tiab] OR craniectom*[tiab]) AND (expectant[tiab] OR "medical treatment"[tiab] OR "medical therapy"[tiab] OR "drug therapy"[Subheading] OR "drug therapy"[tiab] OR "drug therapy"[mesh] OR "steroids"[mesh] OR "mannitol"[mesh] OR "mannitol"[tiab] OR "observation"[mesh] OR "observation"[tiab] OR "non-surgical"[tiab] OR "non-operative"[tiab] OR conservative[tiab] OR conservativ*[tiab] OR "wait and see"[tiab]) AND ("mortality"[Subheading] OR "mortality"[tiab] OR "survival"[tiab] OR "survival"[mesh] OR "Survival Analysis"[Mesh] OR "glasgow outcome scale"[mesh] OR "glasgow outcome"[tiab] OR (Rankin[tiab] AND score[tiab]))) OR (("Hematoma, Subdural"[majr:noexp] OR "Hematoma, Subdural, Acute"[majr] OR "subdural hematoma"[ti] OR "subdural hematomas"[ti] OR "subdural haematoma"[ti] OR "subdural haematomas"[ti] OR "sub dural hematoma"[ti] OR "traumatic subdural hematoma"[ti] OR "post-traumatic subdural hematoma"[ti] OR "subdural bleeding"[ti] OR "subdural haemorrhage"[ti] OR "subdural hemorrhage"[ti] OR ("Hematoma, Subdural"[mesh:noexp] OR "Hematoma, Subdural, Acute"[mesh]) AND ("Hematoma"[majr:noexp] OR "Brain Injuries"[majr:noexp])) OR ("acute"[ti] AND ("subdural"[ti] OR "sub dural"[ti]) AND ("hematoma"[ti] OR "hematomas"[ti] OR "haematoma"[ti] OR "haematomas"[ti] OR "bleeding"[ti] OR "haemorrhage"[ti] OR "hemorrhage"[ti] OR "haemorrhages"[ti] OR "hemorrhages"[ti])) OR ("subdural hematoma"[ti] OR "subdural hematomas"[ti] OR "subdural haematoma"[ti] OR "subdural haematomas"[ti] OR "sub dural hematoma"[ti] OR "traumatic subdural hematoma"[ti] OR "post-traumatic subdural hematoma"[ti] OR "subdural bleeding"[ti] OR "subdural haemorrhage"[ti] OR "subdural hemorrhage"[ti]) AND ("acute subdural hematoma"[tiab] OR "acute subdural hematomas"[tiab] OR "acute subdural haematoma"[tiab] OR "acute subdural haematomas"[tiab] OR "acute sub dural hematoma"[tiab] OR "acute traumatic subdural
```

hematoma"[tiab] OR "acute post-traumatic subdural hematoma"[tiab] OR "acute subdural bleeding"[tiab] OR "acute subdural haemorrhage"[tiab] OR "acute subdural hemorrhage"[tiab])) AND ("prognosis"[mesh] OR "prognosis"[tiab] OR "prognostic"[tiab] OR treatment outcome[tiab] OR "treatment outcome"[mesh] OR outcome[ti] OR outcomes[ti] OR diagnostic feature\*[ti] OR "survival"[tiab] OR "survival"[mesh] OR "Survival Analysis"[Mesh] OR "glasgow outcome scale"[mesh] OR "glasgow outcome"[tiab] OR (Rankin[tiab] AND score[tiab])))) **NOT** ("acute spinal subdural"[ti] OR "acute spontaneous spinal subdural"[ti]) **NOT** (("Case Reports"[publication type] OR case report[ti]) NOT "Clinical Trial"[pt])

## EMBASE

(((((("Subdural Hematoma"/ AND acute.ti) OR "acute subdural hematoma".ti OR "acute subdural hematomas".ti OR "acute subdural haematoma".ti OR "acute subdural haematomas".ti OR "acute sub dural hematoma".ti OR "acute traumatic subdural hematoma".ti OR "acute post-traumatic subdural hematoma".ti OR "acute subdural bleeding".ti OR "acute subdural haemorrhage".ti OR "acute subdural hemorrhage".ti OR ("acute".ti OR acute\*.ti OR "Acute Disease"/) AND ("subdural".ti OR subdural\*.ti OR "sub dural".ti) AND ("hematoma".ti OR "hematomas".ti OR "haematoma".ti OR "haematomas".ti OR hematoma\*.ti OR haematoma\*.ti OR "bleeding".ti OR "haemorrhage".ti OR "hemorrhage".ti OR "hemorrhages".ti OR "haemorrhages".ti)) OR ("Subdural Hematoma"/ AND "Acute Disease"/) AND ("su".fs OR "surgery".mp OR exp "surgery"/ OR "surgical".mp OR neurosurgical.mp OR exp "neurosurgery"/ OR "neurosurgery".mp OR "evacuation".mp OR "craniotomy"/ OR "craniotomy".mp OR craniotom\*.mp OR decompressive.mp OR exp "decompression surgery"/ OR exp "decompression"/ OR "decompression".mp OR hemicraniectomy.mp OR hemicraniectom\*.mp OR craniectomy.mp OR craniectom\*.mp) AND (expectant.mp OR "medical treatment".mp OR "medical therapy".mp OR "dt".fs OR "drug therapy".mp OR exp "drug therapy"/ OR exp "steroid"/ OR "mannitol"/ OR "mannitol".mp OR "observation"/ OR "observation".mp OR "non-surgical".mp OR "non-operative".mp OR conservative.mp OR conservativ\*.mp OR "wait and see".mp OR exp "conservative treatment"/) **OR** (((("Subdural Hematoma"/ AND acute.mp) OR "acute subdural hematoma".mp OR "acute subdural hematomas".mp OR "acute subdural haematoma".mp OR "acute subdural haematomas".mp OR "acute sub dural hematoma".mp OR "acute traumatic subdural hematoma".mp OR "acute subdural bleeding".mp OR "acute subdural haemorrhage".mp OR "acute subdural hemorrhage".mp OR ("acute".mp OR acute\*.mp OR "Acute Disease"/) AND ("subdural".mp OR subdural\*.mp OR "sub dural".mp) AND ("hematoma".mp OR "hematomas".mp OR "haematoma".mp OR "haematomas".mp OR hematoma\*.mp OR haematoma\*.mp OR "bleeding".mp OR "haemorrhage".mp OR "hemorrhage".mp OR "hemorrhages".mp OR "haemorrhages".mp)) OR ("Subdural Hematoma"/ AND "Acute Disease"/) AND ("su".fs OR "surgery".mp OR exp "surgery"/ OR "surgical".mp OR neurosurgical.mp OR exp "neurosurgery"/ OR "neurosurgery".mp OR "evacuation".mp OR "craniotomy"/ OR "craniotomy".mp OR craniotom\*.mp OR decompressive.mp OR exp "decompression surgery"/ OR exp "decompression"/ OR "decompression".mp OR hemicraniectomy.mp OR hemicraniectom\*.mp OR craniectomy.mp OR craniectom\*.mp) AND (expectant.mp OR "medical treatment".mp OR "medical therapy".mp OR "dt".fs OR "drug therapy".mp OR exp "drug therapy"/ OR exp "steroid"/ OR "mannitol"/ OR "mannitol".mp OR "observation"/ OR "observation".mp OR "non-surgical".mp OR "non-operative".mp OR conservative.mp OR conservativ\*.mp OR "wait and see".mp OR exp "conservative treatment"/) AND (exp "mortality"/ OR "mortality".mp OR "survival".mp OR exp "survival"/ OR exp "injury scale"/ OR "glasgow outcome".mp OR (Rankin.mp AND score.mp))) **OR** (((("Subdural Hematoma"/ AND Acute.ti) OR "acute subdural hematoma".ti OR "acute subdural hematomas".ti OR "acute subdural haematoma".ti OR "acute subdural haematomas".ti OR "acute sub dural hematoma".ti OR "acute traumatic subdural hematoma".ti OR "acute post-traumatic subdural hematoma".ti OR "acute subdural bleeding".ti OR "acute subdural haemorrhage".ti OR "acute subdural hemorrhage".ti OR ("acute".ti AND ("subdural".ti OR "sub dural".ti) AND ("hematoma".ti OR "hematomas".ti OR "haematoma".ti OR "haematomas".ti OR "bleeding".ti OR "haemorrhage".ti OR "hemorrhage".ti OR "haemorrhages".ti OR "hemorrhages".ti)) OR ("subdural hematoma".ti OR "subdural hematomas".ti OR "subdural haematoma".ti OR "subdural haematomas".ti OR "sub dural hematoma".ti OR "traumatic subdural hematoma".ti OR "post-traumatic subdural hematoma".ti OR "subdural bleeding".ti OR "subdural haemorrhage".ti OR "subdural hemorrhage".ti) AND ("acute subdural hematoma".ti,ab OR "acute subdural hematomas".ti,ab OR "acute subdural haematoma".ti,ab OR "acute subdural haematomas".ti,ab OR "acute sub dural hematoma".ti,ab OR "acute traumatic subdural hematoma".ti,ab OR "acute post-traumatic subdural hematoma".ti,ab OR "acute subdural



bleeding".ti,ab OR "acute subdural haemorrhage".ti,ab OR "acute subdural hemorrhage".ti,ab))) AND (exp "prognosis"/ OR "prognosis".ti,ab OR "prognostic".ti,ab OR treatment outcome.mp OR exp "treatment outcome"/ OR outcome.ti OR outcomes.ti OR exp "mortality"/ OR "mortality".mp OR "survival".mp OR exp "survival"/ OR exp "injury scale"/ OR "glasgow outcome".mp OR (Rankin.mp AND score.mp))) OR ((\*"head injury"/ AND \*"intracranial pressure"/) AND ("surgery".mp OR exp "surgery"/ OR "surgical".mp OR neurosurgical.mp OR exp "neurosurgery"/ OR "neurosurgery".mp OR "evacuation".mp OR "craniotomy"/ OR "craniotomy".mp OR craniotom\*.mp OR decompressive.mp OR exp "decompression surgery"/ OR exp "decompression"/ OR "decompression".mp OR hemicraniectomy.mp OR hemicraniectom\*.mp OR craniectomy.mp OR craniectom\*.mp) AND exp "clinical study"/ AND (exp "prognosis"/ OR "prognosis".ti,ab OR "prognostic".ti,ab OR treatment outcome.mp OR exp "treatment outcome"/ OR outcome.ti OR outcomes.ti OR exp "mortality"/ OR "mortality".mp OR "survival".mp OR exp "survival"/ OR exp "injury scale"/ OR "glasgow outcome".mp OR (Rankin.mp AND score.mp))) NOT ("acute spinal subdural".ti OR "acute spontaneous spinal subdural".ti) NOT ("Case Report"/ OR case report.ti))

## Web of Science

<http://isiknowledge.com/wos>

((TI=(("Subdural Hematoma" AND acute) OR "acute subdural hematoma" OR "acute subdural hematomas" OR "acute subdural haematoma" OR "acute subdural haematomas" OR "acute sub dural hematoma" OR "acute traumatic subdural hematoma" OR "acute post-traumatic subdural hematoma" OR "acute subdural bleeding" OR "acute subdural haemorrhage" OR "acute subdural hemorrhage" OR ("acute" OR acute\* OR "Acute Disease") AND ("subdural" OR subdural\* OR "sub dural") AND ("hematoma" OR "hematomas" OR "haematoma" OR "haematomas" OR hematoma\* OR haematoma\* OR "bleeding" OR "haemorrhage" OR "hemorrhage" OR "hemorrhages" OR "haemorrhages"))) OR ("Subdural Hematoma" AND "Acute Disease")) AND TS=("surgery" OR "surgery" OR "surgical" OR neurosurgical OR "neurosurgery" OR "neurosurgery" OR "evacuation" OR "craniotomy" OR "craniotomy" OR craniotom\* OR decompressive OR "decompression surgery" OR "decompression" OR "decompression" OR hemicraniectomy OR hemicraniectom\* OR craniectomy OR craniectom\*) AND TS=(expectant OR "medical treatment" OR "medical therapy" OR "drug therapy" OR "drug therapy" OR "steroid" OR "mannitol" OR "mannitol" OR "observation" OR "observation" OR "non-surgical" OR "non-operative" OR conservative OR conservativ\* OR "wait and see" OR "conservative treatment")) **OR** (TS=(("Subdural Hematoma" AND acute) OR "acute subdural hematoma" OR "acute subdural hematomas" OR "acute subdural haematoma" OR "acute subdural haematomas" OR "acute sub dural hematoma" OR "acute traumatic subdural hematoma" OR "acute post-traumatic subdural hematoma" OR "acute subdural bleeding" OR "acute subdural haemorrhage" OR "acute subdural hemorrhage" OR ("acute" OR acute\* OR "Acute Disease") AND ("subdural" OR subdural\* OR "sub dural") AND ("hematoma" OR "hematomas" OR "haematoma" OR "haematomas" OR hematoma\* OR haematoma\* OR "bleeding" OR "haemorrhage" OR "hemorrhage" OR "hemorrhages" OR "haemorrhages"))) OR ("Subdural Hematoma" AND "Acute Disease")) AND TS=("surgery" OR "surgery" OR "surgical" OR neurosurgical OR "neurosurgery" OR "neurosurgery" OR "evacuation" OR "craniotomy" OR "craniotomy" OR craniotom\* OR decompressive OR "decompression surgery" OR "decompression" OR "decompression" OR hemicraniectomy OR hemicraniectom\* OR craniectomy OR craniectom\*) AND TS=(expectant OR "medical treatment" OR "medical therapy" OR "drug therapy" OR "drug therapy" OR "steroid" OR "mannitol" OR "mannitol" OR "observation" OR "observation" OR "non-surgical" OR "non-operative" OR conservative OR conservativ\* OR "wait and see" OR "conservative treatment") AND TS=("mortality" OR "mortality" OR "survival" OR "survival" OR "injury scale" OR "glasgow outcome" OR (Rankin AND score))) **OR** (TI=(("Subdural Hematoma" AND Acute) OR "acute subdural hematoma" OR "acute subdural hematomas" OR "acute subdural haematoma" OR "acute subdural haematomas" OR "acute sub dural hematoma" OR "acute traumatic subdural hematoma" OR "acute post-traumatic subdural hematoma" OR "acute subdural bleeding" OR "acute subdural haemorrhage" OR "acute subdural hemorrhage" OR ("acute" AND ("subdural" OR "sub dural") AND ("hematoma" OR "hematomas" OR "haematoma" OR "haematomas" OR "bleeding" OR "haemorrhage" OR "hemorrhage" OR "haemorrhages" OR "hemorrhages"))) OR ("subdural hematoma" OR "subdural hematomas" OR "subdural haematoma" OR "subdural haematomas" OR "sub dural hematoma" OR "traumatic subdural hematoma" OR "post-traumatic subdural hematoma" OR "subdural bleeding" OR "subdural haemorrhage" OR "subdural hemorrhage") AND ("acute subdural hematoma" OR "acute subdural hematomas" OR "acute subdural haematoma" OR "acute subdural haematomas" OR "acute sub dural hematoma" OR "acute traumatic subdural hematoma"



OR "acute post-traumatic subdural hematoma" OR "acute subdural bleeding" OR "acute subdural haemorrhage" OR "acute subdural hemorrhage")) AND TS=("prognosis" OR "prognosis" OR "prognostic" OR treatment outcome OR "treatment outcome" OR outcome OR outcomes OR "mortality" OR "mortality" OR "survival" OR "survival" OR "injury scale" OR "glasgow outcome" OR (Rankin AND score)))) NOT (TI=("acute spinal subdural" OR "acute spontaneous spinal subdural") OR TI=("Case Report"))

## Cochrane Library

((("Subdural Hematoma" AND acute) OR "acute subdural hematoma" OR "acute subdural hematomas" OR "acute subdural haematoma" OR "acute subdural haematomas" OR "acute sub dural hematoma" OR "acute traumatic subdural hematoma" OR "acute post traumatic subdural hematoma" OR "acute subdural bleeding" OR "acute subdural haemorrhage" OR "acute subdural hemorrhage" OR ("acute" OR acute\* OR "Acute Disease") AND ("subdural" OR subdural\* OR "sub dural") AND ("hematoma" OR "hematomas" OR "haematoma" OR "haematomas" OR hematoma\* OR haematoma\* OR "bleeding" OR "haemorrhage" OR "hemorrhage" OR "hemorrhages" OR "haemorrhages")) OR ("Subdural Hematoma" AND "Acute Disease")) AND ("surgery" OR "surgery" OR "surgical" OR neurosurgical OR "neurosurgery" OR "neurosurgery" OR "evacuation" OR "craniotomy" OR "craniotomy" OR craniotom\* OR decompressive OR "decompression surgery" OR "decompression" OR "decompression" OR hemicraniectomy OR hemicraniectom\* OR craniectomy OR craniectom\*) AND (expectant OR "medical treatment" OR "medical therapy" OR "drug therapy" OR "drug therapy" OR "steroid" OR "mannitol" OR "mannitol" OR "observation" OR "observation" OR "non surgical" OR "non operative" OR conservative OR conservativ\* OR "wait and see" OR "conservative treatment"))  
**OR** ((("Subdural Hematoma" AND acute) OR "acute subdural hematoma" OR "acute subdural hematomas" OR "acute subdural haematoma" OR "acute subdural haematomas" OR "acute sub dural hematoma" OR "acute traumatic subdural hematoma" OR "acute post traumatic subdural hematoma" OR "acute subdural bleeding" OR "acute subdural haemorrhage" OR "acute subdural hemorrhage" OR ("acute" OR acute\* OR "Acute Disease") AND ("subdural" OR subdural\* OR "sub dural") AND ("hematoma" OR "hematomas" OR "haematoma" OR "haematomas" OR hematoma\* OR haematoma\* OR "bleeding" OR "haemorrhage" OR "hemorrhage" OR "hemorrhages" OR "haemorrhages")) OR ("Subdural Hematoma" AND "Acute Disease")) AND ("surgery" OR "surgery" OR "surgical" OR neurosurgical OR "neurosurgery" OR "neurosurgery" OR "evacuation" OR "craniotomy" OR "craniotomy" OR craniotom\* OR decompressive OR "decompression surgery" OR "decompression" OR "decompression" OR hemicraniectomy OR hemicraniectom\* OR craniectomy OR craniectom\*) AND (expectant OR "medical treatment" OR "medical therapy" OR "drug therapy" OR "drug therapy" OR "steroid" OR "mannitol" OR "mannitol" OR "observation" OR "observation" OR "non surgical" OR "non operative" OR conservative OR conservativ\* OR "wait and see" OR "conservative treatment") AND ("mortality" OR "mortality" OR "survival" OR "survival" OR "injury scale" OR "glasgow outcome" OR (Rankin AND score)))  
**OR** ((("Subdural Hematoma" AND Acute) OR "acute subdural hematoma" OR "acute subdural hematomas" OR "acute subdural haematoma" OR "acute subdural haematomas" OR "acute sub dural hematoma" OR "acute traumatic subdural hematoma" OR "acute post traumatic subdural hematoma" OR "acute subdural bleeding" OR "acute subdural haemorrhage" OR "acute subdural hemorrhage" OR ("acute" AND ("subdural" OR "sub dural") AND ("hematoma" OR "hematomas" OR "haematoma" OR "haematomas" OR "bleeding" OR "haemorrhage" OR "hemorrhage" OR "haemorrhages" OR "hemorrhages")) OR ("subdural hematoma" OR "subdural hematomas" OR "subdural haematoma" OR "subdural haematomas" OR "sub dural hematoma" OR "traumatic subdural hematoma" OR "post traumatic subdural hematoma" OR "subdural bleeding" OR "subdural haemorrhage" OR "subdural hemorrhage") AND ("acute subdural hematoma" OR "acute subdural hematomas" OR "acute subdural haematoma" OR "acute subdural haematomas" OR "acute sub dural hematoma" OR "acute traumatic subdural hematoma" OR "acute post traumatic subdural hematoma" OR "acute subdural bleeding" OR "acute subdural haemorrhage" OR "acute subdural hemorrhage")) AND ("prognosis" OR "prognosis" OR "prognostic" OR treatment outcome OR "treatment outcome" OR outcome OR outcomes OR "mortality" OR "mortality" OR "survival" OR "survival" OR "injury scale" OR "glasgow outcome" OR (Rankin AND score)))):ti,ab,kw

## CENTRAL

(((("Subdural Hematoma" AND acute) OR "acute subdural hematoma" OR "acute subdural hematomas" OR "acute subdural haematoma" OR "acute subdural haematomas" OR "acute sub dural hematoma" OR "acute traumatic subdural hematoma" OR "acute post-traumatic subdural hematoma" OR "acute subdural bleeding" OR "acute subdural haemorrhage" OR "acute subdural hemorrhage" OR ("acute" OR acute\* OR "Acute Disease") AND ("subdural" OR subdural\* OR "sub dural") AND ("hematoma" OR "hematomas" OR "haematoma" OR "haematomas" OR hematoma\* OR haematoma\* OR "bleeding" OR "haemorrhage" OR "hemorrhage" OR "hemorrhages" OR "haemorrhages")) OR ("Subdural Hematoma" AND "Acute Disease")) AND ("surgery" OR "surgery" OR "surgical" OR neurosurgical OR "neurosurgery" OR "neurosurgery" OR "evacuation" OR "craniotomy" OR "craniotomy" OR craniotom\* OR decompressive OR "decompression surgery" OR "decompression" OR "decompression" OR hemicraniectomy OR hemicraniectom\* OR craniectomy OR craniectom\*) AND (expectant OR "medical treatment" OR "medical therapy" OR "drug therapy" OR "drug therapy" OR "steroid" OR "mannitol" OR "mannitol" OR "observation" OR "observation" OR "non-surgical" OR "non-operative" OR conservative OR conservativ\* OR "wait and see" OR "conservative treatment"))

**OR** (((("Subdural Hematoma" AND acute) OR "acute subdural hematoma" OR "acute subdural hematomas" OR "acute subdural haematoma" OR "acute subdural haematomas" OR "acute sub dural hematoma" OR "acute traumatic subdural hematoma" OR "acute post-traumatic subdural hematoma" OR "acute subdural bleeding" OR "acute subdural haemorrhage" OR "acute subdural hemorrhage" OR ("acute" OR acute\* OR "Acute Disease") AND ("subdural" OR subdural\* OR "sub dural") AND ("hematoma" OR "hematomas" OR "haematoma" OR "haematomas" OR hematoma\* OR haematoma\* OR "bleeding" OR "haemorrhage" OR "hemorrhage" OR "hemorrhages" OR "haemorrhages")) OR ("Subdural Hematoma" AND "Acute Disease")) AND ("surgery" OR "surgery" OR "surgical" OR neurosurgical OR "neurosurgery" OR "neurosurgery" OR "evacuation" OR "craniotomy" OR "craniotomy" OR craniotom\* OR decompressive OR "decompression surgery" OR "decompression" OR "decompression" OR hemicraniectomy OR hemicraniectom\* OR craniectomy OR craniectom\*) AND (expectant OR "medical treatment" OR "medical therapy" OR "drug therapy" OR "drug therapy" OR "steroid" OR "mannitol" OR "mannitol" OR "observation" OR "observation" OR "non-surgical" OR "non-operative" OR conservative OR conservativ\* OR "wait and see" OR "conservative treatment") AND ("mortality" OR "mortality" OR "survival" OR "survival" OR "injury scale" OR "glasgow outcome" OR (Rankin AND score)))

**OR** (((("Subdural Hematoma" AND Acute) OR "acute subdural hematoma" OR "acute subdural hematomas" OR "acute subdural haematoma" OR "acute subdural haematomas" OR "acute sub dural hematoma" OR "acute traumatic subdural hematoma" OR "acute post-traumatic subdural hematoma" OR "acute subdural bleeding" OR "acute subdural haemorrhage" OR "acute subdural hemorrhage" OR ("acute" AND ("subdural" OR "sub dural") AND ("hematoma" OR "hematomas" OR "haematoma" OR "haematomas" OR "bleeding" OR "haemorrhage" OR "hemorrhage" OR "hemorrhages" OR "haemorrhages")) OR ("subdural hematoma" OR "subdural haematoma" OR "subdural haematomas" OR "sub dural hematoma" OR "traumatic subdural hematoma" OR "post-traumatic subdural hematoma" OR "subdural bleeding" OR "subdural haemorrhage" OR "subdural hemorrhage") AND ("acute subdural hematoma" OR "acute subdural hematomas" OR "acute subdural haematoma" OR "acute subdural haematomas" OR "acute sub dural hematoma" OR "acute traumatic subdural hematoma" OR "acute post-traumatic subdural hematoma" OR "acute subdural bleeding" OR "acute subdural haemorrhage" OR "acute subdural hemorrhage")))) AND ("prognosis" OR "prognosis" OR "prognostic" OR treatment outcome OR "treatment outcome" OR outcome OR outcomes OR "mortality" OR "mortality" OR "survival" OR "survival" OR "injury scale" OR "glasgow outcome" OR (Rankin AND score)))) NOT ("Case Report")

## CINAHL

Search in fields TI (title), MW (subject headings), SU (subject headings and descriptors)

(((("Subdural Hematoma" AND acute) OR "acute subdural hematoma" OR "acute subdural hematomas" OR "acute subdural haematoma" OR "acute subdural haematomas" OR "acute sub dural hematoma" OR "acute traumatic subdural hematoma" OR "acute post-traumatic subdural hematoma" OR "acute subdural bleeding" OR "acute subdural haemorrhage" OR "acute subdural hemorrhage" OR ("acute" OR acute\* OR "Acute Disease") AND ("subdural" OR subdural\* OR "sub dural") AND ("hematoma" OR "hematomas" OR "haematoma" OR "haematomas" OR hematoma\* OR haematoma\* OR "bleeding" OR "haemorrhage" OR "hemorrhage" OR "hemorrhages" OR "haemorrhages")) OR ("Subdural Hematoma" AND "Acute Disease")) AND ("surgery" OR "surgery" OR "surgical" OR neurosurgical OR "neurosurgery" OR "neurosurgery" OR "evacuation" OR "craniotomy" OR

"craniotomy" OR craniotom\* OR decompressive OR "decompression surgery" OR "decompression" OR "decompression" OR hemicraniectomy OR hemicraniectom\* OR craniectomy OR craniectom\*) AND (expectant OR "medical treatment" OR "medical therapy" OR "drug therapy" OR "drug therapy" OR "steroid" OR "mannitol" OR "mannitol" OR "observation" OR "observation" OR "non-surgical" OR "non-operative" OR conservative OR conservativ\* OR "wait and see" OR "conservative treatment")) OR (((("Subdural Hematoma" AND acute) OR "acute subdural hematoma" OR "acute subdural hematomas" OR "acute subdural haematoma" OR "acute subdural haematomas" OR "acute sub dural hematoma" OR "acute traumatic subdural hematoma" OR "acute post-traumatic subdural hematoma" OR "acute subdural bleeding" OR "acute subdural haemorrhage" OR "acute subdural hemorrhage" OR ("acute" OR acute\* OR "Acute Disease") AND ("subdural" OR subdural\* OR "sub dural") AND ("hematoma" OR "hematomas" OR "haematoma" OR "haematomas" OR hematoma\* OR haematoma\* OR "bleeding" OR "haemorrhage" OR "hemorrhage" OR "hemorrhages" OR "haemorrhages")) OR ("Subdural Hematoma" AND "Acute Disease")) AND ("surgery" OR "surgery" OR "surgical" OR neurosurgical OR "neurosurgery" OR "neurosurgery" OR "evacuation" OR "craniotomy" OR "craniotomy" OR craniotom\* OR decompressive OR "decompression surgery" OR "decompression" OR "decompression" OR hemicraniectomy OR hemicraniectom\* OR craniectomy OR craniectom\*) AND (expectant OR "medical treatment" OR "medical therapy" OR "drug therapy" OR "drug therapy" OR "steroid" OR "mannitol" OR "mannitol" OR "observation" OR "observation" OR "non-surgical" OR "non-operative" OR conservative OR conservativ\* OR "wait and see" OR "conservative treatment") AND ("mortality" OR "mortality" OR "survival" OR "survival" OR "injury scale" OR "glasgow outcome" OR (Rankin AND score))) OR (((("Subdural Hematoma" AND Acute) OR "acute subdural hematoma" OR "acute subdural hematomas" OR "acute subdural haematoma" OR "acute subdural haematomas" OR "acute sub dural hematoma" OR "acute traumatic subdural hematoma" OR "acute post-traumatic subdural hematoma" OR "acute subdural bleeding" OR "acute subdural haemorrhage" OR "acute subdural hemorrhage" OR ("acute" AND ("subdural" OR "sub dural") AND ("hematoma" OR "hematomas" OR "haematoma" OR "haematomas" OR "bleeding" OR "haemorrhage" OR "hemorrhage" OR "haemorrhages" OR "hemorrhages")) OR ("subdural hematoma" OR "subdural hematomas" OR "subdural haematoma" OR "subdural haematomas" OR "sub dural hematoma" OR "traumatic subdural hematoma" OR "post-traumatic subdural hematoma" OR "subdural bleeding" OR "subdural haemorrhage" OR "subdural hemorrhage") AND ("acute subdural hematoma" OR "acute subdural hematomas" OR "acute subdural haematoma" OR "acute subdural haematomas" OR "acute sub dural hematoma" OR "acute traumatic subdural hematoma" OR "acute post-traumatic subdural hematoma" OR "acute subdural bleeding" OR "acute subdural haemorrhage" OR "acute subdural hemorrhage")))) AND ("prognosis" OR "prognosis" OR "prognostic" OR treatment outcome OR "treatment outcome" OR outcome OR outcomes OR "mortality" OR "mortality" OR "survival" OR "survival" OR "injury scale" OR "glasgow outcome" OR (Rankin AND score)))) NOT ("Case Report")

## Academic Search Premier

Search in fields TI (title), KW (key words), SU (subject headings)

(((("Subdural Hematoma" AND acute) OR "acute subdural hematoma" OR "acute subdural hematomas" OR "acute subdural haematoma" OR "acute subdural haematomas" OR "acute sub dural hematoma" OR "acute traumatic subdural hematoma" OR "acute post-traumatic subdural hematoma" OR "acute subdural bleeding" OR "acute subdural haemorrhage" OR "acute subdural hemorrhage" OR ("acute" OR acute\* OR "Acute Disease") AND ("subdural" OR subdural\* OR "sub dural") AND ("hematoma" OR "hematomas" OR "haematoma" OR "haematomas" OR hematoma\* OR haematoma\* OR "bleeding" OR "haemorrhage" OR "hemorrhage" OR "hemorrhages" OR "haemorrhages")) OR ("Subdural Hematoma" AND "Acute Disease")) AND ("surgery" OR "surgery" OR "surgical" OR neurosurgical OR "neurosurgery" OR "neurosurgery" OR "evacuation" OR "craniotomy" OR "craniotomy" OR craniotom\* OR decompressive OR "decompression surgery" OR "decompression" OR "decompression" OR hemicraniectomy OR hemicraniectom\* OR craniectomy OR craniectom\*) AND (expectant OR "medical treatment" OR "medical therapy" OR "drug therapy" OR "drug therapy" OR "steroid" OR "mannitol" OR "mannitol" OR "observation" OR "observation" OR "non-surgical" OR "non-operative" OR conservative OR conservativ\* OR "wait and see" OR "conservative treatment")) OR (((("Subdural Hematoma" AND acute) OR "acute subdural hematoma" OR "acute subdural hematomas" OR "acute subdural haematoma" OR "acute subdural haematomas" OR "acute sub dural hematoma" OR "acute traumatic subdural hematoma" OR "acute post-traumatic subdural hematoma" OR "acute subdural bleeding" OR "acute subdural haemorrhage" OR "acute subdural hemorrhage" OR "acute subdural hemorrhage" OR "acute subdural haemorrhage" OR "acute subdural hemorrhage")) AND ("prognosis" OR "prognosis" OR "prognostic" OR treatment outcome OR "treatment outcome" OR outcome OR outcomes OR "mortality" OR "mortality" OR "survival" OR "survival" OR "injury scale" OR "glasgow outcome" OR (Rankin AND score)))) NOT ("Case Report")

OR (("acute" OR acute\* OR "Acute Disease") AND ("subdural" OR subdural\* OR "sub dural") AND ("hematoma" OR "hematomas" OR "haematoma" OR "haematomas" OR hematoma\* OR haematoma\* OR "bleeding" OR "haemorrhage" OR "hemorrhage" OR "hemorrhages" OR "haemorrhages")) OR ("Subdural Hematoma" AND "Acute Disease")) AND ("surgery" OR "surgery" OR "surgical" OR neurosurgical OR "neurosurgery" OR "neurosurgery" OR "evacuation" OR "craniotomy" OR "craniotomy" OR craniotom\* OR decompressive OR "decompression surgery" OR "decompression" OR "decompression" OR hemicraniectomy OR hemicraniectom\* OR craniectomy OR craniectom\*) AND (expectant OR "medical treatment" OR "medical therapy" OR "drug therapy" OR "drug therapy" OR "steroid" OR "mannitol" OR "mannitol" OR "observation" OR "observation" OR "non-surgical" OR "non-operative" OR conservative OR conservativ\* OR "wait and see" OR "conservative treatment") AND ("mortality" OR "mortality" OR "survival" OR "survival" OR "injury scale" OR "glasgow outcome" OR (Rankin AND score))) OR (((("Subdural Hematoma" AND Acute) OR "acute subdural hematoma" OR "acute subdural hematomas" OR "acute subdural haematoma" OR "acute subdural haematomas" OR "acute sub dural hematoma" OR "acute traumatic subdural hematoma" OR "acute post-traumatic subdural hematoma" OR "acute subdural bleeding" OR "acute subdural haemorrhage" OR "acute subdural hemorrhage" OR ("acute" AND ("subdural" OR "sub dural") AND ("hematoma" OR "hematomas" OR "haematoma" OR "haematomas" OR "bleeding" OR "haemorrhage" OR "hemorrhage" OR "haemorrhages" OR "hemorrhages")) OR ("subdural hematoma" OR "subdural hematomas" OR "subdural haematoma" OR "subdural haematomas" OR "sub dural hematoma" OR "traumatic subdural hematoma" OR "post-traumatic subdural hematoma" OR "subdural bleeding" OR "subdural haemorrhage" OR "subdural hemorrhage") AND ("acute subdural hematoma" OR "acute subdural hematomas" OR "acute subdural haematoma" OR "acute subdural haematomas" OR "acute sub dural hematoma" OR "acute traumatic subdural hematoma" OR "acute post-traumatic subdural hematoma" OR "acute subdural bleeding" OR "acute subdural haemorrhage" OR "acute subdural hemorrhage")))) AND ("prognosis" OR "prognosis" OR "prognostic" OR treatment outcome OR "treatment outcome" OR outcome OR outcomes OR "mortality" OR "mortality" OR "survival" OR "survival" OR "injury scale" OR "glasgow outcome" OR (Rankin AND score)))) NOT ("Case Report")

## ScienceDirect

TITLE-ABSTR-KEY(("acute subdural hematoma" OR "acute subdural hematomas" OR "acute subdural haematoma" OR "acute subdural haematomas" OR "acute sub dural hematoma" OR "acute traumatic subdural hematoma" OR "acute post-traumatic subdural hematoma" OR "acute subdural bleeding" OR "acute subdural haemorrhage" OR "acute subdural hemorrhage") AND ("surgery" OR "surgery" OR "surgical" OR neurosurgical OR "neurosurgery" OR "neurosurgery" OR "evacuation" OR "craniotomy" OR "craniotomy" OR craniotom\* OR decompressive OR "decompression surgery" OR "decompression" OR "decompression" OR hemicraniectomy OR hemicraniectom\* OR craniectomy OR craniectom\*) AND (expectant OR "medical treatment" OR "medical therapy" OR "drug therapy" OR "drug therapy" OR "steroid" OR "mannitol" OR "mannitol" OR "observation" OR "observation" OR "non-surgical" OR "non-operative" OR conservative OR conservativ\* OR "wait and see" OR "conservative treatment"))

## Google Scholar

allintitle: "treatment" "acute subdural hematoma"

allintitle: "surgery" "acute subdural hematoma"

allintitle: "therapy" "acute subdural hematoma"

## IndexCat

"SUB-DURAL" OR SUBDURAL OR "intra dural" OR "INTRA-DURAL" OR intracranial AND hematoma OR intracranial AND haematoma OR intracranial AND hematoma OR intracranial AND haematoma OR intracranial AND hemorrhage OR intracranial AND haemorrhage OR intracranial AND bleeding OR intracranial AND hæmorrhage OR "intra-cranial" AND hematoma OR "intra-cranial" AND haematoma OR "intra-cranial" AND hematoma OR "intra-cranial" AND haematoma OR "intra-cranial"

AND hemorrhage OR "intra-cranial" AND haemorrhage OR "intra-cranial" AND bleeding OR "intra-cranial" AND hæmorrhage

## 6. References

- 1 Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. *JAMA* 2007; **297**: 278–85.
- 2 Brookhart MA, Rassen JA, Schneeweiss S. Instrumental variable methods in comparative safety and effectiveness research. *Pharmacoepidem Drug Safe* 2010; **19**: 537–54.
- 3 Cnossen MC, van Essen TA, Ceyisakar IE, *et al.* Adjusting for confounding by indication in observational studies: a case study in traumatic brain injury. *Clinical Epidemiology* 2018; **10**: 841–52.
- 4 Nagelkerke N. A note on a general definition of the coefficient of determination. *Biometrika* 1991; **78**: 691–2.
- 5 Davies NM, Smith GD, Windmeijer F, Martin RM. Issues in the reporting and conduct of instrumental variable studies: a systematic review. *Epidemiology* 2013; **24**: 363–9.
- 6 MRC CRASH Trial Collaborators. Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients. *BMJ* 2008; **336**: 425–9.
- 7 Essen TA, Boogert HF, Cnossen MC, *et al.* Variation in neurosurgical management of traumatic brain injury: a survey in 68 centers participating in the CENTER-TBI study. 2018; : 1–15.
- 8 Swanson SA, Robins JM, Miller M, Hernán MA. Selecting on Treatment: A Pervasive Form of Bias in Instrumental Variable Analyses. *American Journal of Epidemiology* 2015; **181**: 191–7.